{"gene":"FOXE1","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1997,"finding":"TTF-2 (FOXE1) is a forkhead domain-containing transcription factor that binds to sites on both thyroglobulin (Tg) and thyroperoxidase (TPO) promoters. Its expression is transient in the developing thyroid and is down-regulated just before the onset of Tg and TPO gene expression, suggesting it acts as a negative controller of thyroid-specific gene expression during development.","method":"cDNA cloning, DNA binding assays, expression analysis by in situ hybridization in mouse embryos","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — original cloning paper with direct DNA binding assays and in vivo expression mapping; foundational study replicated by subsequent work","pmids":["9214635"],"is_preprint":false},{"year":1997,"finding":"TTF-2 (FOXE1) mRNA levels are under transcriptional control by TSH (via cAMP), insulin, and IGF-I in FRTL-5 thyroid cells. TSH and insulin effects are additive, require ongoing protein synthesis, and increase TTF-2 transcription rates as demonstrated by run-off assays.","method":"Northern blot, nuclear run-off transcription assays, dose-response experiments in FRTL-5 thyroid cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct transcription rate measurement by run-off assay combined with dose-response and protein synthesis inhibition in a well-established thyroid cell model","pmids":["9287345"],"is_preprint":false},{"year":1998,"finding":"A homozygous missense mutation (Ala65Val) within the FOXE1 forkhead domain causes thyroid agenesis, cleft palate, and choanal atresia. The mutant protein exhibits impaired DNA binding and loss of transcriptional function.","method":"Patient sequencing, in vitro DNA binding assays, transcriptional reporter assays with mutant protein","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — functional validation by direct DNA binding and transcription assays combined with human genetics; replicated in subsequent mutation reports","pmids":["9697705"],"is_preprint":false},{"year":1999,"finding":"TTF-2 (FOXE1) physically interacts with CTF/NF-1 proteins (specifically CTF/NF1-C, which is itself TSH-, cAMP-, and insulin-inducible) via GST pull-down. This interaction enhances hormone-induced TPO gene expression; spacing between the two transcription factor binding sites is critical for promoter activity and hormonal response.","method":"GST pull-down assays, transfection experiments, protein-DNA interaction studies, spacing mutagenesis of TPO promoter","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — direct physical interaction demonstrated by GST pulldown; functional consequence confirmed by promoter mutagenesis and transfection in a single rigorous study","pmids":["10329730"],"is_preprint":false},{"year":2000,"finding":"TTF-2 (FOXE1) acts as a promoter-specific transcriptional repressor of TTF-1 and Pax-8 activity through a DNA-binding-independent mechanism. The minimal repressor domain was identified as an independent functional domain that interferes with a specific cofactor required for TTF-1 and Pax-8 activity.","method":"Transcriptional reporter assays, deletion mutagenesis to map repressor domain, co-transfection experiments","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional repressor domain mapped by mutagenesis with reporter assays, but single lab and limited orthogonal validation","pmids":["10944465"],"is_preprint":false},{"year":2002,"finding":"A second homozygous missense mutation in TTF-2/FOXE1 (Ser57Asn in the forkhead DNA binding domain) causes congenital hypothyroidism, athyreosis, and cleft palate. The S57N mutant protein shows impaired DNA binding and partial loss of transcriptional function, correlating with a less severe phenotype than the A65V mutation.","method":"Patient sequencing, in vitro DNA binding assays, transcriptional reporter assays","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — functional DNA binding and transcription assays; genotype-phenotype correlation across two distinct mutations establishes structure-function relationship","pmids":["12165566"],"is_preprint":false},{"year":2002,"finding":"TTF-2/FOXE1 protein is phosphorylated in vivo and is expressed in multiple endoderm-derived structures during mouse embryogenesis (tongue, palate, epiglottis, pharynx, oesophagus, choanae) and ectodermal structures (whiskers), consistent with the full phenotypic spectrum of Bamforth syndrome.","method":"Detailed immunohistochemistry of mouse embryos at multiple developmental stages, phosphorylation detection","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — phosphorylation of TTF-2 shown by fractionation/immunodetection; expression pattern established by systematic IHC across embryogenesis in a focused study","pmids":["12203737"],"is_preprint":false},{"year":2004,"finding":"FOXE1 is a direct transcriptional target of GLI2 in the Sonic Hedgehog signaling pathway in human epidermis. A 2.5 kb upstream fragment containing five GLI-binding sites activates FOXE1 transcription in a reporter assay, with induction kinetics similar to the known direct GLI2 target PTCH.","method":"Reporter assays with GLI-binding site-containing FOXE1 upstream fragment, in situ hybridization, kinetic expression analysis","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay with defined binding sites plus expression co-localization; single lab, two complementary methods","pmids":["15140221"],"is_preprint":false},{"year":2004,"finding":"Foxe1 is required for hair follicle morphogenesis downstream of the Shh/Gli pathway. In Foxe1-null mice, hair follicles are disoriented and misaligned. Dominant-negative Gli2 suppresses Foxe1 expression in hair follicles, and transcriptionally active Gli2 stimulates the Foxe1 promoter.","method":"Foxe1-null mouse analysis, dominant-negative Gli2 transgenic mice, Foxe1 promoter reporter assays, immunohistochemistry, lineage marker expression analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — loss-of-function mouse model with defined phenotype, epistasis established by dominant-negative approach, and promoter assay; multiple orthogonal methods in one study","pmids":["15367491"],"is_preprint":false},{"year":2006,"finding":"A third homozygous missense mutation in FOXE1 (R102C, within the forkhead DNA binding domain) causes loss of DNA binding and transcriptional inactivity but does not prevent thyroid tissue formation, indicating that human thyroid development can occur despite loss of TTF-2/FOXE1 function.","method":"Patient sequencing, in vitro DNA binding assay, transcriptional reporter assays","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — same functional assay platform replicated across three independent mutations; mechanistically informative negative phenotype (thyroid present despite null function)","pmids":["16882747"],"is_preprint":false},{"year":2007,"finding":"FoxE1 acts as a pioneer transcription factor: it binds to the compacted chromatin of the inactive TPO promoter upon hormone induction, creates a local exposed chromatin domain on H1-compacted nucleosome arrays even when its binding site is nucleosome-protected, and enables NF-1 to bind simultaneously with an additive effect on chromatin remodeling.","method":"Chromatin DNase I hypersensitivity assay in thyroid cells, in vitro nucleosome binding assays, in vitro H1-compacted chromatin assays, cotransfection/binding with NF-1","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with nucleosomes plus cell-based chromatin assays with multiple orthogonal methods in one rigorous study","pmids":["17709379"],"is_preprint":false},{"year":2007,"finding":"The FOXE1 polyalanine tract length modulates transcriptional activity: constructs with 16 alanines show 1.55-fold higher transcriptional activity than those with 14 alanines, while nuclear localization is not affected. The 16/16 genotype is associated with protection against thyroid dysgenesis.","method":"Transcriptional reporter assays with FOXE1 constructs containing 14 or 16 alanines, nuclear localization assessment, case-control and TDT association study","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assay directly comparing alanine tract variants; single lab, supported by genetic association data","pmids":["17717707"],"is_preprint":false},{"year":2009,"finding":"The FOXE1 5' UTR variant rs1867277 (NM_004473.3:c.-283G>A) differentially recruits transcription factors: the A allele exclusively recruits USF1/USF2, while both alleles form a complex with DREAM/CREB/αCREM. Transfection studies show allele-dependent transcriptional regulation of FOXE1.","method":"DNA-binding (EMSA) assays, transfection reporter assays, candidate gene association study in Spanish and Italian cohorts","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct protein-DNA binding assays (EMSA) combined with functional transcription assays and replicated genetic association; multiple orthogonal methods","pmids":["19730683"],"is_preprint":false},{"year":2009,"finding":"In non-syndromic cleft palate patients, a C→G polymorphism in the 5'-UTR of FOXE1 falls within a MYF-5 consensus binding motif and abolishes MYF-5 binding (demonstrated by EMSA), resulting in significantly reduced FOXE1 mRNA expression.","method":"DNA sequencing, EMSA/band-shift assays, oligonucleotide competition, real-time PCR","journal":"Journal of oral pathology & medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA directly demonstrates abolished MYF-5 binding with functional mRNA consequence; single lab","pmids":["19192046"],"is_preprint":false},{"year":2009,"finding":"In zebrafish, foxe1 loss-of-function (morpholino knockdown) causes abnormal craniofacial development with shortening of Meckel's cartilage and ceratohyals, suppressed chondrocytic proliferation, and reduced expression of sox9a, colIIa1, and runx2b at 2 dpf, while upregulating fgfr2 in branchial arches. Neural crest migration and pharyngeal arch specification are unaffected.","method":"Morpholino antisense knockdown in zebrafish, in situ hybridization for marker genes, cartilage staining","journal":"Journal of experimental zoology. Part B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific molecular marker readouts; zebrafish morpholino approach, single lab","pmids":["19488987"],"is_preprint":false},{"year":2010,"finding":"FOXE1 directly transactivates MSX1 and TGF-β3 promoters by binding to specific motifs, as demonstrated by ChIP and promoter reporter assays. Forkhead-domain mutations (but not polyalanine stretch polymorphisms) abolish this activity. In Foxe1-null mouse embryos (E14), Tgf-β3 and Msx1 mRNAs are nearly absent in palatal shelves, establishing these as direct FOXE1 targets required for palatogenesis.","method":"Chromatin immunoprecipitation (ChIP), promoter reporter (transactivation) assays, Foxe1-null mouse embryo analysis by RT-PCR, mutagenesis of forkhead domain","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — ChIP plus reporter assays plus in vivo knockout validation; multiple orthogonal methods with mutagenesis","pmids":["21177256"],"is_preprint":false},{"year":2010,"finding":"A fourth homozygous FOXE1 missense mutation (F137S, caused by maternal isodisomy of chromosome 9) abolishes DNA binding and transcriptional activity as predicted by structural modeling and confirmed by transfection assays.","method":"Sequencing, microsatellite marker analysis, MLPA, structural modeling, transfection transcriptional assays","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional validation by transcription assay plus structural modeling; confirms established pattern across four independent mutations","pmids":["20484477"],"is_preprint":false},{"year":2012,"finding":"FOXE1 polyalanine tract length affects transcriptional function: in vitro studies show FOXE1(16Ala) is transcriptionally impaired compared to FOXE1(14Ala), without differences in protein expression or DNA binding, suggesting the alanine tract modulates a step after DNA binding (e.g., cofactor interaction or transactivation).","method":"In vitro transcriptional reporter assays, protein expression analysis, DNA binding assays comparing different polyalanine tract length variants","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — three functional parameters measured to localize the functional defect; single lab","pmids":["22736773"],"is_preprint":false},{"year":2013,"finding":"FoxE1 directly binds the NIS (Nis) upstream enhancer and the Duox2 regulatory region in thyroid cells (demonstrated by ChIP), with simultaneous binding of FoxE1 and NF1/CTF to the Nis enhancer having an additive functional effect on Nis promoter activation. Genome-wide expression screening after FoxE1 knockdown identified multiple regulated targets including Adamts9, Cdh1, Duox2, S100a4 (upregulated) and Casp4, Creld2, Dusp5, Etv5, Hsp5a, Nr4a2, Tm4sf1 (downregulated).","method":"Genome-wide expression screening after FoxE1 knockdown, ChIP assay, in silico promoter analysis, luciferase reporter assays","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — ChIP demonstrates direct genomic binding, combined with genome-wide knockdown expression profiling and reporter assays; multiple orthogonal methods in one study","pmids":["23675434"],"is_preprint":false},{"year":2014,"finding":"Methylation of two consecutive CpG dinucleotides (CpG14 and CpG15) in the FOXE1 promoter (-1600 to -1140 from TSS) is significantly higher in leukocytes than in thyroid tissue, and this methylation reduces FOXE1 promoter activity in luciferase assays. Preventing methylation of these sites by mutation restores promoter activity.","method":"Genome-wide methylation array, bisulfite sequencing, luciferase reporter assays with methylated and unmethylated FOXE1 promoter constructs, site-directed mutagenesis of CpG sites","journal":"The Journal of clinical endocrinology and metabolism","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro methylation + reporter assay with mutagenesis directly demonstrates functional consequence of specific CpG methylation; multiple orthogonal methods","pmids":["24646064"],"is_preprint":false},{"year":2015,"finding":"A non-coding SNP (rs7850258) within a -67.7 kb FOXE1 enhancer element active in oral epithelium and developing thyroid alters enhancer activity in an allele-dependent manner: the G allele (associated with CLP and hypothyroidism) has significantly greater enhancer activity than the A allele (associated with thyroid cancer). The element is more responsive to MYC and ARNT with the G allele, as predicted by transcription factor binding differences.","method":"Zebrafish and mouse transgenesis to identify enhancers, quantitative reporter assays in oral epithelial and thyroid cell lines comparing both alleles, transcription factor binding prediction","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo enhancer identification by transgenesis in two model organisms plus quantitative reporter assays; directly links non-coding variant to FOXE1 expression differences","pmids":["25652407"],"is_preprint":false},{"year":2015,"finding":"FOXE1 somatic mutations in papillary thyroid cancer (P54Q, K95Q, L112F in PTC; G140R in MNG) within the forkhead domain result in marked impairment of transcriptional activation without affecting protein expression, as demonstrated by in vitro functional assays and molecular modeling.","method":"Sequencing of 120 PTC and 110 MNG samples, in vitro transcriptional activation assays, FOXE1 forkhead domain structural modeling","journal":"Thyroid","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays for all four mutants; molecular modeling provides structural rationale; single lab","pmids":["25950909"],"is_preprint":false},{"year":2015,"finding":"FOXE1 germline variant p.A248G promotes cell proliferation and migration in rat normal thyroid cells (PCCL3) and human PTC cell line (TPC-1), suggesting a gain-of-function or altered function in thyroid tumorigenesis.","method":"Stable expression of wild-type and p.A248G mutant FOXE1 in thyroid cell lines, proliferation and migration assays","journal":"Endocrine","confidence":"Low","confidence_rationale":"Tier 3 / Weak — cell-based proliferation and migration assays without mechanistic pathway identification; single lab, single functional readout","pmids":["25381600"],"is_preprint":false},{"year":2015,"finding":"FOXE1 expression is regulated by TSH/cAMP via CREB and CREM binding to CRE sites in the Foxe1 promoter, and by TGF-β via SMAD proteins that inhibit TSH-induced Foxe1 expression. Foxe1 is also regulated by Nkx2-1, Pax8, and by itself (autoregulation), establishing a complex transcriptional network for Foxe1 control in thyroid follicular cells.","method":"Promoter cloning, site-directed mutagenesis of CRE and SMAD binding sites, protein/DNA binding assays, siRNA gene silencing of CREB/CREM/Smad/Nkx2-1/Pax8, reporter assays in PCCl3 thyroid cells","journal":"Thyroid","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — systematic promoter mutagenesis combined with binding assays and siRNA knockdown of each regulatory factor; multiple orthogonal methods in one study","pmids":["30652527"],"is_preprint":false},{"year":2015,"finding":"Nitric oxide (NO) inhibits TSH-stimulated TPO expression by repressing FoxE1 expression through a cGMP-dependent protein kinase-mediated pathway. The FoxE1 binding site Z in the TPO promoter mediates the NO-inhibited TPO expression.","method":"NO donor treatment of FRTL-5 thyroid cells, cGMP-PKG pathway inhibitor studies, promoter binding site mutation analysis, FoxE1 expression measurement","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with specific binding site identified as mediator; single lab but mechanistically defined pathway","pmids":["26610751"],"is_preprint":false},{"year":2016,"finding":"FOXE1 physically interacts with ELK1 (identified in a transcription factor binding array, confirmed by co-immunoprecipitation and mammalian two-hybrid assay). In thyroid tissue, endogenous FOXE1 and ELK1 bind the TERT and TPO promoters in close proximity (ChIP assay). FOXE1 positively regulates TERT expression in a manner dependent on its association with ELK1; MEK inhibition (U0126) disrupts the FOXE1-ELK1 interaction and reduces TERT and TPO promoter activity.","method":"Transcription factor binding array, co-immunoprecipitation, mammalian two-hybrid assay, ChIP in human thyroid tissue, EMSA, TERT promoter reporter assays, siRNA silencing, MEK inhibitor treatment","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — physical interaction confirmed by reciprocal co-IP and two-hybrid; ChIP in native tissue; functional consequence shown by reporter assay and siRNA; multiple orthogonal methods","pmids":["27852061"],"is_preprint":false},{"year":2016,"finding":"Foxe1 overexpression in mouse thyroid (under thyroglobulin promoter) causes early severe hypothyroidism and thyroid hypoplasia, then multinodular goiter with macrofollicular-papilloid benign nodules in adult mice. Combined with radiation or Pten haploinsufficiency, Foxe1 overexpression promotes hyperplastic but not malignant nodule formation, indicating proper Foxe1 dosage is essential for normal thyroid structure and function.","method":"Transgenic mouse model (Tg-Foxe1), thyroid hormone measurement, histological analysis, radiation exposure experiments, crossing with Pten+/- mice","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo transgenic model with quantitative hormone measurement and histology; multiple genetic backgrounds tested; direct dose-effect demonstrated","pmids":["26982637"],"is_preprint":false},{"year":2017,"finding":"PTCSC2 lncRNA binds MYH9 (myosin-9) protein. In a bidirectional promoter shared by FOXE1 and PTCSC2, MYH9 inhibits promoter activity in both directions; PTCSC2 reverses this inhibition. RNA knockdown of FOXE1 in primary thyroid cells profoundly interferes with the p53 pathway.","method":"RNA pull-down/binding assay (PTCSC2-MYH9 interaction), bidirectional promoter reporter assays, siRNA knockdown of FOXE1 with pathway gene expression analysis","journal":"Proceedings of the National Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-protein binding and promoter reporter assays demonstrated; FOXE1 knockdown pathway effect shown; single lab","pmids":["28049826"],"is_preprint":false},{"year":2019,"finding":"FOXE1 directly binds the HK2 promoter and negatively regulates HK2 transcription, thereby suppressing the Warburg effect (aerobic glycolysis) in colorectal cancer cells. Silencing FOXE1 enhances glucose consumption and lactate production, while enforced FOXE1 expression has opposite effects.","method":"ChIP assay showing FOXE1 binding to HK2 promoter, luciferase reporter assays, FOXE1 knockdown/overexpression with metabolic measurements, in vivo xenograft","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrates direct promoter binding; functional metabolic phenotype confirmed in vitro and in vivo; single lab","pmids":["31918722"],"is_preprint":false},{"year":2020,"finding":"FOXE1 directly interacts with the ZEB1 promoter (confirmed by ChIP) and positively regulates ZEB1 transcriptional activity. Loss of FOXE1 decreases ZEB1 expression, while FOXE1 overexpression increases ZEB1 activity. ZEB1 silencing reduces thyroid tumor cell migration and invasion, placing FOXE1 upstream of ZEB1 in an EMT regulatory pathway.","method":"ChIP assay, gain-of-function and loss-of-function experiments, ZEB1 reporter assays, migration/invasion assays, siRNA silencing of ZEB1 and FOXE1","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirms direct binding; epistasis established by sequential knockdown; functional readout in migration/invasion; single lab","pmids":["31846430"],"is_preprint":false},{"year":2020,"finding":"Reducing FOXE1 gene dosage (FOXE1+/- background) in a BRAFV600E-inducible thyroid cancer mouse model changes cancer histology: FOXE1+/+ cancers resemble high-grade papillary thyroid carcinomas while FOXE1+/- cancers are morphologically less malignant but more severely undifferentiated, with reduced proliferation and increased apoptosis. FOXE1 dosage thus exerts pleiotropic effects on thyroid cancer histology and differentiation markers.","method":"Genetic epistasis in compound transgenic mouse model, histological analysis, proliferation index (Ki67), apoptosis assay, immunohistochemistry for differentiation markers","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean genetic dosage experiment in defined in vivo cancer model with multiple phenotypic readouts; single lab","pmids":["33375029"],"is_preprint":false},{"year":2021,"finding":"FOXE1 expression in thyroid cells (that do not endogenously express FOXE1) upregulates multiple chemokines involved in macrophage recruitment. FOXE1-expressing cells induce chemotaxis of co-cultured monocytes. In a mouse thyroid cancer model, FOXE1 dosage directly correlates with expression of the same chemokine set, and pro-tumorigenic M2 macrophage infiltration is decreased in tumors with reduced FOXE1.","method":"Transcriptome analysis (RNA-seq) after FOXE1 expression in FOXE1-negative cells, monocyte chemotaxis co-culture assay, in vivo mouse cancer model with FOXE1+/- background, immunohistochemistry for macrophage markers","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transcriptomic plus functional chemotaxis assay plus in vivo validation; single lab but multiple orthogonal methods","pmids":["34299284"],"is_preprint":false},{"year":2022,"finding":"Tamoxifen-inducible ubiquitous deletion of Foxe1 in adult mice causes disrupted thyroid follicular architecture, elevated TSH, reduced T4, decreased Tpo and Tg expression, and an unexpected increase in thyroidal mast cells (marked by Mcpt4 and Ctsg), confirming Foxe1's role in maintenance of thyroid differentiation in adults.","method":"Conditional knockout mouse model (Cre-lox/tamoxifen inducible), hormone measurements, histology, immunohistochemistry, microarray and RNA-seq transcriptomics, RT-qPCR validation","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible conditional knockout with multiple functional readouts (hormone levels, histology, transcriptomics) confirms adult role; mechanistically links FOXE1 loss to mast cell infiltration","pmids":["36156081"],"is_preprint":false},{"year":2023,"finding":"FOXE1 promotes keratinocyte proliferation by facilitating G1/S transition and activating ERK1/2 signaling, and upregulates the production of IL-1β, IL-6, and TNF-α. RNA-seq identifies WNT5A as a downstream effector; WNT5A knockdown inhibits FOXE1-driven keratinocyte proliferation and cytokine production. In vivo, FOXE1 depletion by shRNA or genetic deletion ameliorates imiquimod-induced psoriasis-like dermatitis.","method":"Knockdown and overexpression of FOXE1 in keratinocytes, RNA-seq, cell cycle analysis, ERK1/2 phosphorylation assay, WNT5A siRNA rescue experiment, imiquimod mouse model with lentiviral shRNA or genetic FOXE1 deletion","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq identifies WNT5A as downstream target; epistasis confirmed by rescue experiment; in vivo validation in mouse model; single lab","pmids":["37394057"],"is_preprint":false},{"year":2011,"finding":"HR (Hairless) transcriptional cofactor suppresses Foxe1 mRNA expression in skin; Foxe1 downregulation in turn reduces Msx1 expression in hair follicles, placing HR upstream of Foxe1 and Msx1 in a hair follicle regulatory cascade. Sfrp1 expression also correlates with Foxe1 levels.","method":"Expression analysis in HR-overexpressing mouse skin and keratinocytes, correlation of Foxe1 and downstream target gene expression","journal":"BMB reports","confidence":"Low","confidence_rationale":"Tier 3 / Weak — correlation of expression in overexpression model without direct mechanistic binding or epistasis experiment; single lab, single method","pmids":["21777520"],"is_preprint":false}],"current_model":"FOXE1 (TTF-2) is a forkhead domain transcription factor that functions as a pioneer factor in thyroid differentiation—binding compacted chromatin at the TPO promoter to enable access by other factors—and directly activates transcription of thyroid differentiation genes (TPO, Tg, NIS, Duox2) while repressing others (HK2); its transcription is induced by TSH/cAMP (via CREB/CREM), insulin/IGF-I, and thyroid transcription factors Nkx2-1 and Pax8 (with autoregulation), and is inhibited by TGF-β/SMAD and nitric oxide; FOXE1 physically interacts with CTF/NF-1 and ELK1 to co-regulate target promoters (including TERT), and co-regulates ZEB1, MSX1, TGF-β3, and chemokines involved in macrophage recruitment; loss-of-function mutations in its forkhead domain abolish DNA binding and cause congenital hypothyroidism with thyroid agenesis, cleft palate, and choanal atresia (Bamforth-Lazarus syndrome), while proper gene dosage is essential for normal thyroid architecture in adults, and non-coding variants near FOXE1 alter enhancer activity to modulate susceptibility to thyroid cancer, hypothyroidism, and orofacial clefting."},"narrative":{"mechanistic_narrative":"FOXE1 (TTF-2) is a forkhead-domain transcription factor that orchestrates thyroid follicular cell differentiation and is also required for craniofacial and skin development [PMID:9214635, PMID:9697705]. It functions as a pioneer factor, binding the compacted, nucleosome-protected chromatin of the inactive TPO promoter upon hormone induction to create a locally accessible chromatin domain that enables co-occupancy by NF-1/CTF, with additive effects on chromatin remodeling and target activation [PMID:17709379, PMID:10329730]. Through its forkhead domain it directly binds and transactivates a battery of thyroid differentiation genes including TPO, Tg, the NIS enhancer, and Duox2 [PMID:9214635, PMID:23675434], and during palatogenesis it directly drives MSX1 and TGF-β3 [PMID:21177256]; conversely it represses targets such as HK2 to restrain aerobic glycolysis [PMID:31918722]. FOXE1 also partners with ELK1 to co-occupy and activate the TERT and TPO promoters in a MEK-dependent manner [PMID:27852061], and acts upstream of ZEB1 in an EMT/migration program [PMID:31846430]. FOXE1 transcription is itself a signaling integration node: it is induced by TSH/cAMP through CREB/CREM and by insulin/IGF-I, autoregulated and co-controlled by Nkx2-1 and Pax8, and inhibited by TGF-β/SMAD and by nitric oxide via cGMP-dependent kinase [PMID:9287345, PMID:30652527, PMID:26610751], with additional control by GLI2/Sonic Hedgehog in epidermis [PMID:15140221, PMID:15367491]. Homozygous missense mutations in the forkhead domain abolish DNA binding and transcriptional activity and cause Bamforth-Lazarus syndrome—congenital hypothyroidism with thyroid agenesis, cleft palate, and choanal atresia [PMID:9697705, PMID:12165566, PMID:16882747, PMID:20484477]. Proper FOXE1 gene dosage is essential for normal thyroid architecture, hormone production, and tumor differentiation in adults, and non-coding variants near FOXE1 alter enhancer or promoter activity to modulate susceptibility to thyroid dysgenesis, thyroid cancer, hypothyroidism, and orofacial clefting [PMID:26982637, PMID:36156081, PMID:25652407, PMID:19730683].","teleology":[{"year":1997,"claim":"Established the molecular identity of FOXE1 as a forkhead transcription factor that physically binds thyroid-specific promoters, defining its core activity in thyroid gene regulation.","evidence":"cDNA cloning, DNA-binding assays, and in situ hybridization in mouse embryos","pmids":["9214635"],"confidence":"High","gaps":["Direct vs. repressive role on target genes ambiguous from expression timing alone","No structural definition of DNA-binding specificity"]},{"year":1997,"claim":"Defined the upstream signaling inputs by showing FOXE1 transcription is hormonally controlled, linking it to thyroid-stimulating and growth-factor signaling.","evidence":"Northern blot and nuclear run-off transcription assays in FRTL-5 thyroid cells","pmids":["9287345"],"confidence":"High","gaps":["Promoter elements mediating TSH/insulin response not yet mapped","Transcription factors transducing the signal unidentified"]},{"year":1998,"claim":"Connected FOXE1 to human disease by demonstrating that a forkhead-domain mutation abolishing DNA binding causes thyroid agenesis with cleft palate, establishing FOXE1 as causative for Bamforth-Lazarus syndrome.","evidence":"Patient sequencing with in vitro DNA-binding and transcriptional reporter assays of the A65V mutant","pmids":["9697705"],"confidence":"High","gaps":["Single mutation; allelic series not yet established","Mechanism linking loss of binding to specific tissue agenesis unknown"]},{"year":1999,"claim":"Identified the first FOXE1 protein partner, showing it cooperates with hormone-inducible CTF/NF-1 to potentiate TPO promoter activity in a spacing-dependent manner.","evidence":"GST pull-down, TPO promoter spacing mutagenesis, and transfection assays","pmids":["10329730"],"confidence":"High","gaps":["Whether cooperation requires chromatin context not addressed","Endogenous co-occupancy not yet shown"]},{"year":2000,"claim":"Revealed a DNA-binding-independent repressor function, showing FOXE1 can interfere with TTF-1/Pax-8 cofactors and thereby has dual activator/repressor capacity.","evidence":"Deletion mutagenesis mapping a repressor domain with co-transfection reporter assays","pmids":["10944465"],"confidence":"Medium","gaps":["The targeted cofactor not identified","Single lab, limited orthogonal validation"]},{"year":2002,"claim":"Built a genotype-phenotype structure-function relationship by correlating a partial-function forkhead mutation (S57N) with a milder phenotype than A65V.","evidence":"Patient sequencing with DNA-binding and reporter assays","pmids":["12165566"],"confidence":"High","gaps":["Residual function quantification approximate","Modifiers of phenotype severity unknown"]},{"year":2002,"claim":"Mapped FOXE1 expression beyond thyroid to multiple endoderm- and ectoderm-derived structures and showed it is phosphorylated, explaining the syndromic phenotypic spectrum.","evidence":"Systematic immunohistochemistry across mouse embryogenesis plus phosphorylation detection","pmids":["12203737"],"confidence":"Medium","gaps":["Phosphorylation sites and kinases not identified","Functional consequence of phosphorylation unknown"]},{"year":2004,"claim":"Placed FOXE1 downstream of Sonic Hedgehog by identifying it as a direct GLI2 target and a requirement for hair follicle morphogenesis, defining a non-thyroid developmental role.","evidence":"GLI-site reporter assays, Foxe1-null mice, and dominant-negative/active Gli2 epistasis","pmids":["15140221","15367491"],"confidence":"High","gaps":["FOXE1 effector genes in follicle morphogenesis not defined here","Direct GLI2 occupancy at the FOXE1 locus not shown by ChIP"]},{"year":2006,"claim":"Refined the developmental requirement by showing a complete loss-of-function mutation (R102C) still permits thyroid tissue formation in humans, indicating FOXE1 is dispensable for organ initiation but required for proper differentiation.","evidence":"Patient sequencing with DNA-binding and reporter assays","pmids":["16882747"],"confidence":"High","gaps":["Why this null allele spares thyroid tissue unexplained","Possible compensatory factors unidentified"]},{"year":2007,"claim":"Defined the central mechanistic insight that FOXE1 is a pioneer factor, binding compacted chromatin to open it and license NF-1 co-binding, explaining how it initiates thyroid gene activation.","evidence":"DNase I hypersensitivity in thyroid cells and in vitro H1-compacted nucleosome reconstitution with NF-1","pmids":["17709379"],"confidence":"High","gaps":["Chromatin remodelers recruited not identified","Genome-wide pioneer activity not assessed"]},{"year":2007,"claim":"Showed the FOXE1 polyalanine tract length tunes transcriptional output independent of localization, linking a coding polymorphism to thyroid dysgenesis risk.","evidence":"Reporter assays comparing 14- vs 16-alanine constructs with case-control/TDT association","pmids":["17717707"],"confidence":"Medium","gaps":["Mechanism of alanine-tract effect not pinpointed (resolved later)","Direction of effect later refined"]},{"year":2009,"claim":"Demonstrated that non-coding regulatory variants modulate FOXE1 dosage by altering transcription factor recruitment, mechanistically connecting GWAS associations to FOXE1 expression in thyroid and cleft phenotypes.","evidence":"EMSA and reporter assays for the rs1867277 5'UTR variant (USF1/USF2, DREAM/CREB/CREM) and a cleft-associated UTR variant abolishing MYF-5 binding","pmids":["19730683","19192046"],"confidence":"High","gaps":["In vivo allelic expression effect in human tissue not directly measured","Cell-type specificity of factor recruitment incomplete"]},{"year":2009,"claim":"Extended the craniofacial role across species by showing foxe1 loss impairs cartilage development and chondrocyte gene expression in zebrafish.","evidence":"Morpholino knockdown with marker in situ hybridization and cartilage staining","pmids":["19488987"],"confidence":"Medium","gaps":["Morpholino specificity not genetically confirmed","Direct vs indirect regulation of sox9a/runx2b unresolved"]},{"year":2010,"claim":"Identified the direct palatogenesis target genes by showing FOXE1 binds and activates MSX1 and TGF-β3, which are lost in Foxe1-null palatal shelves, mechanistically explaining the cleft phenotype.","evidence":"ChIP, promoter reporter assays, forkhead-domain mutagenesis, and Foxe1-null embryo RT-PCR","pmids":["21177256"],"confidence":"High","gaps":["Whether pioneer activity operates at these promoters not tested","Cofactor requirements at MSX1/TGF-β3 unknown"]},{"year":2010,"claim":"Added a fourth disease allele (F137S via uniparental isodisomy) reinforcing that forkhead-domain integrity is essential for DNA binding and transactivation.","evidence":"Sequencing, structural modeling, and transcription assays","pmids":["20484477"],"confidence":"Medium","gaps":["Structural model not experimentally validated","Single lab"]},{"year":2012,"claim":"Localized the polyalanine-tract functional defect to a step downstream of DNA binding, refining how this coding variant modulates transactivation.","evidence":"Reporter assays comparing 14- vs 16-alanine variants with parallel protein-expression and DNA-binding measurements","pmids":["22736773"],"confidence":"Medium","gaps":["Specific cofactor or transactivation step affected unidentified","Apparent direction differs from earlier study without reconciliation"]},{"year":2013,"claim":"Broadened the direct thyroid target repertoire genome-wide, showing FOXE1 binds the NIS enhancer and Duox2 region (with NF-1 additivity) and regulates many genes, consolidating its master role in follicular differentiation.","evidence":"Genome-wide expression profiling after FoxE1 knockdown plus ChIP and luciferase reporter assays","pmids":["23675434"],"confidence":"High","gaps":["Direct vs indirect status of most knockdown-responsive genes unresolved","Genome-wide binding map not generated"]},{"year":2014,"claim":"Showed promoter CpG methylation silences FOXE1, adding an epigenetic layer that may explain tissue-restricted expression.","evidence":"Bisulfite sequencing and reporter assays with methylated/mutated CpG14/15 constructs","pmids":["24646064"],"confidence":"High","gaps":["Enzymes establishing methylation not identified","In vivo methylation dynamics during development not traced"]},{"year":2015,"claim":"Resolved how a single non-coding enhancer SNP can drive opposite disease associations by showing allele-dependent enhancer activity and differential MYC/ARNT responsiveness in oral and thyroid tissue.","evidence":"Zebrafish/mouse transgenesis enhancer mapping with allele-specific reporter assays","pmids":["25652407"],"confidence":"High","gaps":["Endogenous chromatin contacts to the FOXE1 promoter not mapped","Quantitative effect on native FOXE1 levels not measured"]},{"year":2015,"claim":"Linked FOXE1 to cancer by showing somatic forkhead-domain mutations in papillary thyroid carcinoma impair transactivation, implicating loss of FOXE1 differentiation function in tumorigenesis.","evidence":"Tumor sequencing with transcription assays and structural modeling","pmids":["25950909"],"confidence":"Medium","gaps":["Downstream targets affected by these mutations not defined","Driver vs passenger status not established"]},{"year":2015,"claim":"Defined the TSH/cAMP and TGF-β/NO regulatory circuitry controlling FOXE1, establishing it as an integration point for opposing thyroid signals.","evidence":"Promoter CRE/SMAD mutagenesis, binding assays, siRNA of CREB/CREM/SMAD/Nkx2-1/Pax8 in PCCl3 cells, and NO/cGMP-PKG pharmacology in FRTL-5 cells","pmids":["30652527","26610751"],"confidence":"High","gaps":["Quantitative hierarchy among inputs not established","Crosstalk with chromatin/methylation control not integrated"]},{"year":2016,"claim":"Identified ELK1 as a MEK-dependent FOXE1 partner co-regulating TERT and TPO, linking FOXE1 to telomerase control and MAPK signaling in thyroid cells.","evidence":"TF binding array, reciprocal co-IP, mammalian two-hybrid, ChIP in human thyroid tissue, reporter assays, siRNA, and MEK inhibition","pmids":["27852061"],"confidence":"High","gaps":["Whether the interaction is direct or bridged not fully resolved","Phosphorylation sites mediating MEK dependence unmapped"]},{"year":2016,"claim":"Demonstrated that FOXE1 dosage is critical for thyroid architecture, with overexpression causing hypothyroidism, hypoplasia, and benign nodular disease.","evidence":"Tg-Foxe1 transgenic mice with hormone measurement, histology, radiation, and Pten+/- crosses","pmids":["26982637"],"confidence":"High","gaps":["Molecular mediators of dosage sensitivity not defined","Overexpression did not produce malignancy, leaving cancer role open"]},{"year":2017,"claim":"Connected FOXE1 to its bidirectional partner lncRNA PTCSC2 and the p53 pathway, adding a regulatory and tumor-suppressive dimension to the locus.","evidence":"PTCSC2-MYH9 RNA pull-down, bidirectional promoter reporter assays, and FOXE1 knockdown pathway profiling","pmids":["28049826"],"confidence":"Medium","gaps":["Mechanism linking FOXE1 to p53 genes not defined","Single lab"]},{"year":2019,"claim":"Revealed a metabolic regulatory role by showing FOXE1 directly represses HK2 to suppress the Warburg effect in colorectal cancer.","evidence":"ChIP, reporter assays, FOXE1 gain/loss with metabolic readouts and xenografts","pmids":["31918722"],"confidence":"Medium","gaps":["Whether repression uses the DNA-binding-independent mechanism unknown","Generalizability beyond colorectal context untested"]},{"year":2020,"claim":"Placed FOXE1 upstream of ZEB1 in an EMT program, providing a mechanism for FOXE1 influence on thyroid tumor migration and invasion.","evidence":"ChIP, ZEB1 reporter assays, sequential siRNA epistasis, and migration/invasion assays","pmids":["31846430"],"confidence":"Medium","gaps":["Direct vs cooperative activation of ZEB1 not fully distinguished","Single lab"]},{"year":2020,"claim":"Showed FOXE1 dosage exerts pleiotropic effects on cancer histology and differentiation in a BRAF-driven model, clarifying its role in tumor phenotype rather than initiation.","evidence":"Genetic dosage epistasis in BRAFV600E mice with proliferation, apoptosis, and marker analysis","pmids":["33375029"],"confidence":"Medium","gaps":["Target genes mediating histological shift not identified","Single lab"]},{"year":2021,"claim":"Linked FOXE1 to the tumor immune microenvironment by showing it drives chemokine expression and macrophage recruitment in a dosage-dependent manner.","evidence":"RNA-seq after FOXE1 expression, monocyte chemotaxis co-culture, and FOXE1+/- mouse cancer model with macrophage IHC","pmids":["34299284"],"confidence":"Medium","gaps":["Direct chemokine promoter targets not all validated","Whether effect is thyroid-specific unknown"]},{"year":2022,"claim":"Established a continued adult requirement by showing inducible Foxe1 deletion disrupts thyroid architecture, lowers hormone output, and unexpectedly increases mast cells.","evidence":"Tamoxifen-inducible conditional knockout with hormone, histology, and transcriptomic analyses","pmids":["36156081"],"confidence":"High","gaps":["Mechanism of mast cell accumulation unknown","Direct vs indirect basis of differentiation-gene loss not parsed"]},{"year":2023,"claim":"Defined a pro-inflammatory skin role, showing FOXE1 drives keratinocyte proliferation and cytokine production via ERK1/2 and WNT5A and promotes psoriasis-like dermatitis.","evidence":"FOXE1 gain/loss in keratinocytes, RNA-seq, WNT5A rescue, and imiquimod mouse model with shRNA/genetic deletion","pmids":["37394057"],"confidence":"Medium","gaps":["Whether WNT5A is a direct FOXE1 target not shown","Single lab"]},{"year":null,"claim":"How FOXE1 pioneer activity is mechanistically coupled to specific chromatin remodelers, post-translational modifications, and its switch between activation and repression across tissues remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified remodeling complex recruited by FOXE1","Phosphorylation sites and their regulatory roles unmapped","Determinants selecting activator vs repressor mode unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,2,15,18,23,28]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,2,5,9,10]},{"term_id":"GO:0140097","term_label":"catalytic activity, acting on DNA","supporting_discovery_ids":[3,25]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,11]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,10,15,18,23]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[10,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,14,15]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,7,23,24,25]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,5,9,21]}],"complexes":[],"partners":["NF1","CTF","ELK1","MYH9","USF1","USF2","CREB","MYF5"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00358","full_name":"Forkhead box protein E1","aliases":["Forkhead box protein E2","Forkhead-related protein FKHL15","HFKH4","HNF-3/fork head-like protein 5","HFKL5","Thyroid transcription factor 2","TTF-2"],"length_aa":373,"mass_kda":38.1,"function":"Transcription factor that binds consensus sites on a variety of gene promoters and activate their transcription. Involved in proper palate formation, most probably through the expression of MSX1 and TGFB3 genes which are direct targets of this transcription factor. Also implicated in thyroid gland morphogenesis. May indirectly play a role in cell growth and migration through the regulation of WNT5A expression","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O00358/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FOXE1","classification":"Not Classified","n_dependent_lines":9,"n_total_lines":1208,"dependency_fraction":0.0074503311258278145},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FOXE1","total_profiled":1310},"omim":[{"mim_id":"620900","title":"SHORT TANDEM REPEAT, TTTG(4), THYROID-SPECIFIC; STRTS","url":"https://www.omim.org/entry/620900"},{"mim_id":"616534","title":"THYROID CANCER, NONMEDULLARY, 4; NMTC4","url":"https://www.omim.org/entry/616534"},{"mim_id":"614821","title":"PTCSC3 GENE; PTCSC3","url":"https://www.omim.org/entry/614821"},{"mim_id":"609893","title":"HYPOTHYROIDISM, CONGENITAL, NONGOITROUS, 3; CHNG3","url":"https://www.omim.org/entry/609893"},{"mim_id":"605597","title":"FORKHEAD TRANSCRIPTION FACTOR FOXL2; FOXL2","url":"https://www.omim.org/entry/605597"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"thyroid gland","ntpm":182.0}],"url":"https://www.proteinatlas.org/search/FOXE1"},"hgnc":{"alias_symbol":["TTF-2","HFKH4"],"prev_symbol":["FKHL15","TITF2","FOXE2"]},"alphafold":{"accession":"O00358","domains":[{"cath_id":"1.10.10.10","chopping":"59-150","consensus_level":"high","plddt":88.8426,"start":59,"end":150}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00358","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00358-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00358-F1-predicted_aligned_error_v6.png","plddt_mean":60.12},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FOXE1","jax_strain_url":"https://www.jax.org/strain/search?query=FOXE1"},"sequence":{"accession":"O00358","fasta_url":"https://rest.uniprot.org/uniprotkb/O00358.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00358/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00358"}},"corpus_meta":[{"pmid":"9697705","id":"PMC_9697705","title":"Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia.","date":"1998","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9697705","citation_count":301,"is_preprint":false},{"pmid":"9214635","id":"PMC_9214635","title":"TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9214635","citation_count":219,"is_preprint":false},{"pmid":"18084247","id":"PMC_18084247","title":"Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/18084247","citation_count":204,"is_preprint":false},{"pmid":"21981779","id":"PMC_21981779","title":"Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21981779","citation_count":201,"is_preprint":false},{"pmid":"19730683","id":"PMC_19730683","title":"The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors.","date":"2009","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19730683","citation_count":132,"is_preprint":false},{"pmid":"19779022","id":"PMC_19779022","title":"FOXE1 association with both isolated cleft lip with or without cleft palate, and isolated cleft palate.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19779022","citation_count":131,"is_preprint":false},{"pmid":"20350937","id":"PMC_20350937","title":"The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20350937","citation_count":131,"is_preprint":false},{"pmid":"12165566","id":"PMC_12165566","title":"A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12165566","citation_count":114,"is_preprint":false},{"pmid":"25303483","id":"PMC_25303483","title":"Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.","date":"2015","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25303483","citation_count":86,"is_preprint":false},{"pmid":"28049826","id":"PMC_28049826","title":"MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28049826","citation_count":80,"is_preprint":false},{"pmid":"12203737","id":"PMC_12203737","title":"Distribution of the titf2/foxe1 gene product is consistent with an important role in the development of foregut endoderm, palate, and hair.","date":"2002","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/12203737","citation_count":79,"is_preprint":false},{"pmid":"15140221","id":"PMC_15140221","title":"FOXE1, a new transcriptional target of GLI2 is expressed in human epidermis and basal cell carcinoma.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15140221","citation_count":79,"is_preprint":false},{"pmid":"21730105","id":"PMC_21730105","title":"The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21730105","citation_count":72,"is_preprint":false},{"pmid":"17709379","id":"PMC_17709379","title":"The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17709379","citation_count":68,"is_preprint":false},{"pmid":"9287345","id":"PMC_9287345","title":"Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9287345","citation_count":64,"is_preprint":false},{"pmid":"25381600","id":"PMC_25381600","title":"Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).","date":"2014","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/25381600","citation_count":55,"is_preprint":false},{"pmid":"9169137","id":"PMC_9169137","title":"FKHL15, a new human member of the forkhead gene family located on chromosome 9q22.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9169137","citation_count":54,"is_preprint":false},{"pmid":"17717707","id":"PMC_17717707","title":"Polymorphic length of FOXE1 alanine stretch: evidence for genetic susceptibility to thyroid dysgenesis.","date":"2007","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17717707","citation_count":54,"is_preprint":false},{"pmid":"15367491","id":"PMC_15367491","title":"Requirement of the forkhead gene Foxe1, a target of sonic hedgehog signaling, in hair follicle morphogenesis.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15367491","citation_count":53,"is_preprint":false},{"pmid":"24105688","id":"PMC_24105688","title":"Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24105688","citation_count":52,"is_preprint":false},{"pmid":"23675434","id":"PMC_23675434","title":"New insights into FoxE1 functions: identification of direct FoxE1 targets in thyroid cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23675434","citation_count":50,"is_preprint":false},{"pmid":"10944465","id":"PMC_10944465","title":"The thyroid transcription factor 2 (TTF-2) is a promoter-specific DNA-binding independent transcriptional repressor.","date":"2000","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10944465","citation_count":50,"is_preprint":false},{"pmid":"10403172","id":"PMC_10403172","title":"Cloning, chromosomal localization and identification of polymorphisms in the human thyroid transcription factor 2 gene (TITF2).","date":"1999","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/10403172","citation_count":49,"is_preprint":false},{"pmid":"22736773","id":"PMC_22736773","title":"Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22736773","citation_count":49,"is_preprint":false},{"pmid":"22882326","id":"PMC_22882326","title":"FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.","date":"2012","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22882326","citation_count":48,"is_preprint":false},{"pmid":"24563486","id":"PMC_24563486","title":"Strong association of variants around FOXE1 and orofacial clefting.","date":"2014","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/24563486","citation_count":48,"is_preprint":false},{"pmid":"16882747","id":"PMC_16882747","title":"A novel missense mutation in human TTF-2 (FKHL15) gene associated with congenital hypothyroidism but not athyreosis.","date":"2006","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/16882747","citation_count":45,"is_preprint":false},{"pmid":"30941771","id":"PMC_30941771","title":"MicroRNA-524-5p suppresses the progression of papillary thyroid carcinoma cells via targeting on FOXE1 and ITGA3 in cell autophagy and cycling pathways.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30941771","citation_count":44,"is_preprint":false},{"pmid":"21177256","id":"PMC_21177256","title":"MSX1 and TGF-beta3 are novel target genes functionally regulated by FOXE1.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21177256","citation_count":43,"is_preprint":false},{"pmid":"10329730","id":"PMC_10329730","title":"The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10329730","citation_count":42,"is_preprint":false},{"pmid":"20453517","id":"PMC_20453517","title":"Spectrum of Human Foxe1/TTF2 Mutations.","date":"2010","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20453517","citation_count":41,"is_preprint":false},{"pmid":"21462296","id":"PMC_21462296","title":"Variation in FGF1, FOXE1, and TIMP2 genes is associated with nonsyndromic cleft lip with or without cleft palate.","date":"2011","source":"Birth defects research. Part A, Clinical and molecular teratology","url":"https://pubmed.ncbi.nlm.nih.gov/21462296","citation_count":39,"is_preprint":false},{"pmid":"19845668","id":"PMC_19845668","title":"FOXE1 is a target for aberrant methylation in cutaneous squamous cell carcinoma.","date":"2009","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19845668","citation_count":39,"is_preprint":false},{"pmid":"25652407","id":"PMC_25652407","title":"A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25652407","citation_count":37,"is_preprint":false},{"pmid":"24127282","id":"PMC_24127282","title":"The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.","date":"2013","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24127282","citation_count":37,"is_preprint":false},{"pmid":"23327367","id":"PMC_23327367","title":"Patterns of FOXE1 expression in papillary thyroid carcinoma by immunohistochemistry.","date":"2013","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/23327367","citation_count":32,"is_preprint":false},{"pmid":"24280874","id":"PMC_24280874","title":"FOXE1 and SYNE1 genes hypermethylation panel as promising biomarker in colitis-associated colorectal neoplasia.","date":"2014","source":"Inflammatory bowel diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24280874","citation_count":32,"is_preprint":false},{"pmid":"31918722","id":"PMC_31918722","title":"FOXE1 represses cell proliferation and Warburg effect by inhibiting HK2 in colorectal cancer.","date":"2020","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/31918722","citation_count":29,"is_preprint":false},{"pmid":"19488987","id":"PMC_19488987","title":"Forkhead transcription factor foxe1 regulates chondrogenesis in zebrafish.","date":"2009","source":"Journal of experimental zoology. Part B, Molecular and developmental evolution","url":"https://pubmed.ncbi.nlm.nih.gov/19488987","citation_count":28,"is_preprint":false},{"pmid":"21896990","id":"PMC_21896990","title":"Genetic investigation of FOXE1 polyalanine tract in thyroid diseases: new insight on the role of FOXE1 in thyroid carcinoma.","date":"2010","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/21896990","citation_count":27,"is_preprint":false},{"pmid":"24756757","id":"PMC_24756757","title":"Relationships of FOXE1 and ATM genetic polymorphisms with papillary thyroid carcinoma risk: a meta-analysis.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24756757","citation_count":26,"is_preprint":false},{"pmid":"31846430","id":"PMC_31846430","title":"FOXE1 regulates migration and invasion in thyroid cancer cells and targets ZEB1.","date":"2020","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31846430","citation_count":24,"is_preprint":false},{"pmid":"17318017","id":"PMC_17318017","title":"TTF-2/FOXE1 gene polymorphisms in Sicilian patients with permanent primary congenital hypothyroidism.","date":"2007","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17318017","citation_count":24,"is_preprint":false},{"pmid":"20484477","id":"PMC_20484477","title":"Maternal isodisomy for chromosome 9 causing homozygosity for a novel FOXE1 mutation in syndromic congenital hypothyroidism.","date":"2010","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20484477","citation_count":22,"is_preprint":false},{"pmid":"28455095","id":"PMC_28455095","title":"Next-generation sequencing of NKX2.1, FOXE1, PAX8, NKX2.5, and TSHR in 100 Chinese patients with congenital hypothyroidism and athyreosis.","date":"2017","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28455095","citation_count":21,"is_preprint":false},{"pmid":"31129275","id":"PMC_31129275","title":"FOXE1 inhibits cell proliferation, migration and invasion of papillary thyroid cancer by regulating PDGFA.","date":"2019","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31129275","citation_count":20,"is_preprint":false},{"pmid":"24489898","id":"PMC_24489898","title":"Quantitative assessment of common genetic variants on FOXE1 and differentiated thyroid cancer risk.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24489898","citation_count":20,"is_preprint":false},{"pmid":"30793770","id":"PMC_30793770","title":"FOXE1 supports the tumor promotion of Gli2 on papillary thyroid carcinoma by the Wnt/β-catenin pathway.","date":"2019","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30793770","citation_count":20,"is_preprint":false},{"pmid":"26610751","id":"PMC_26610751","title":"Nitric oxide-repressed Forkhead factor FoxE1 expression is involved in the inhibition of TSH-induced thyroid peroxidase levels.","date":"2015","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26610751","citation_count":19,"is_preprint":false},{"pmid":"15320969","id":"PMC_15320969","title":"Genetic analysis of TTF-2 gene in children with congenital hypothyroidism and cleft palate, congenital hypothyroidism, or isolated cleft palate.","date":"2004","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/15320969","citation_count":19,"is_preprint":false},{"pmid":"26756829","id":"PMC_26756829","title":"The Sclerotinia sclerotiorum FoxE2 Gene Is Required for Apothecial Development.","date":"2016","source":"Phytopathology","url":"https://pubmed.ncbi.nlm.nih.gov/26756829","citation_count":18,"is_preprint":false},{"pmid":"37394057","id":"PMC_37394057","title":"FOXE1 Contributes to the Development of Psoriasis by Regulating WNT5A.","date":"2023","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37394057","citation_count":17,"is_preprint":false},{"pmid":"23715628","id":"PMC_23715628","title":"Expression and clinical significance of FOXE1 in papillary thyroid carcinoma.","date":"2013","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/23715628","citation_count":17,"is_preprint":false},{"pmid":"30652527","id":"PMC_30652527","title":"Regulation of Foxe1 by Thyrotropin and Transforming Growth Factor Beta Depends on the Interplay Between Thyroid-Specific, CREB and SMAD Transcription Factors.","date":"2019","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/30652527","citation_count":17,"is_preprint":false},{"pmid":"27852061","id":"PMC_27852061","title":"Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27852061","citation_count":16,"is_preprint":false},{"pmid":"24646064","id":"PMC_24646064","title":"Role for tissue-dependent methylation differences in the expression of FOXE1 in nontumoral thyroid glands.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24646064","citation_count":16,"is_preprint":false},{"pmid":"24744143","id":"PMC_24744143","title":"Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24744143","citation_count":15,"is_preprint":false},{"pmid":"19192046","id":"PMC_19192046","title":"Altered binding of MYF-5 to FOXE1 promoter in non-syndromic and CHARGE-associated cleft palate.","date":"2009","source":"Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19192046","citation_count":14,"is_preprint":false},{"pmid":"26722557","id":"PMC_26722557","title":"The investigation of foxe1 variations in papillary thyroid carcinoma.","date":"2015","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26722557","citation_count":13,"is_preprint":false},{"pmid":"33375029","id":"PMC_33375029","title":"FOXE1 Gene Dosage Affects Thyroid Cancer Histology and Differentiation In Vivo.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33375029","citation_count":12,"is_preprint":false},{"pmid":"25950909","id":"PMC_25950909","title":"Somatic Mutations of FOXE1 in Papillary Thyroid Cancer.","date":"2015","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/25950909","citation_count":12,"is_preprint":false},{"pmid":"26982637","id":"PMC_26982637","title":"Targeted Foxe1 Overexpression in Mouse Thyroid Causes the Development of Multinodular Goiter But Does Not Promote Carcinogenesis.","date":"2016","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26982637","citation_count":12,"is_preprint":false},{"pmid":"27824288","id":"PMC_27824288","title":"Genotype Analyses in the Japanese and Belarusian Populations Reveal Independent Effects of rs965513 and rs1867277 but Do Not Support the Role of FOXE1 Polyalanine Tract Length in Conferring Risk for Papillary Thyroid Carcinoma.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27824288","citation_count":12,"is_preprint":false},{"pmid":"29788924","id":"PMC_29788924","title":"Exploration of the association between FOXE1 gene polymorphism and differentiated thyroid cancer: a meta-analysis.","date":"2018","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29788924","citation_count":11,"is_preprint":false},{"pmid":"22304410","id":"PMC_22304410","title":"Overexpression of mouse TTF-2 gene causes cleft palate.","date":"2012","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22304410","citation_count":11,"is_preprint":false},{"pmid":"26100861","id":"PMC_26100861","title":"Association between FOXE1 and non-syndromic orofacial clefts in a northeastern Chinese population.","date":"2015","source":"The British journal of oral & maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/26100861","citation_count":11,"is_preprint":false},{"pmid":"32141546","id":"PMC_32141546","title":"MiRNA-802 inhibits the metastasis of colorectal cancer by targeting FOXE1.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32141546","citation_count":10,"is_preprint":false},{"pmid":"15223130","id":"PMC_15223130","title":"TTF-2 stimulates expression of 17 genes, including one novel thyroid-specific gene which might be involved in thyroid development.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15223130","citation_count":10,"is_preprint":false},{"pmid":"27604706","id":"PMC_27604706","title":"Genetic variation of FOXE1 and risk for orofacial clefts in a California population.","date":"2016","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/27604706","citation_count":9,"is_preprint":false},{"pmid":"16172985","id":"PMC_16172985","title":"Xenopus laevis FoxE1 is primarily expressed in the developing pituitary and thyroid.","date":"2005","source":"The International journal of developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/16172985","citation_count":9,"is_preprint":false},{"pmid":"27755953","id":"PMC_27755953","title":"Profiling analysis of FOX gene family members identified FOXE1 as potential regulator of NSCLC development.","date":"2016","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/27755953","citation_count":8,"is_preprint":false},{"pmid":"19930442","id":"PMC_19930442","title":"Investigation into FOXE1 genetic variations in cutaneous squamous cell carcinoma.","date":"2009","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19930442","citation_count":8,"is_preprint":false},{"pmid":"9446794","id":"PMC_9446794","title":"TTF-2 does not appear to be a key mediator of the effect of cyclic AMP on thyroglobulin gene transcription in primary cultured dog thyrocytes.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9446794","citation_count":8,"is_preprint":false},{"pmid":"21777520","id":"PMC_21777520","title":"Downregulation of Foxe1 by HR suppresses Msx1 expression in the hair follicles of Hr(Hp) mice.","date":"2011","source":"BMB reports","url":"https://pubmed.ncbi.nlm.nih.gov/21777520","citation_count":8,"is_preprint":false},{"pmid":"27610545","id":"PMC_27610545","title":"FOXE1 Polymorphism Interacts with Dietary Iodine Intake in Differentiated Thyroid Cancer Risk in the Cuban Population.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27610545","citation_count":8,"is_preprint":false},{"pmid":"36156081","id":"PMC_36156081","title":"Foxe1 Deletion in the Adult Mouse Is Associated With Increased Thyroidal Mast Cells and Hypothyroidism.","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36156081","citation_count":7,"is_preprint":false},{"pmid":"27877282","id":"PMC_27877282","title":"Theoretical study of the zero-gap organic conductor α-(BEDT-TTF)2I3.","date":"2009","source":"Science and technology of advanced materials","url":"https://pubmed.ncbi.nlm.nih.gov/27877282","citation_count":7,"is_preprint":false},{"pmid":"38396644","id":"PMC_38396644","title":"Identification of Germline FOXE1 and Somatic MAPK Pathway Gene Alterations in Patients with Malignant Struma Ovarii, Cleft Palate and Thyroid Cancer.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38396644","citation_count":6,"is_preprint":false},{"pmid":"34306074","id":"PMC_34306074","title":"Hsa-miR-330-5p Aggravates Thyroid Carcinoma via Targeting FOXE1.","date":"2021","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34306074","citation_count":6,"is_preprint":false},{"pmid":"36308369","id":"PMC_36308369","title":"The Effect of LL37 Antimicrobial Peptide on FOXE1 and lncRNA PTCSC 2 Genes Expression in Colorectal Cancer (CRC) and Normal Cells.","date":"2022","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/36308369","citation_count":6,"is_preprint":false},{"pmid":"16584930","id":"PMC_16584930","title":"FOXE1 gene mutation screening by multiplex PCR/DHPLC in CHARGE syndrome and syndromic and non-syndromic cleft palate.","date":"2006","source":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16584930","citation_count":6,"is_preprint":false},{"pmid":"28102383","id":"PMC_28102383","title":"Understanding room-temperature π-dimerisation of radical ions: intramolecular π-[TTF]22+ in functionalised calix[4]arenes.","date":"2017","source":"Physical chemistry chemical physics : PCCP","url":"https://pubmed.ncbi.nlm.nih.gov/28102383","citation_count":6,"is_preprint":false},{"pmid":"28727628","id":"PMC_28727628","title":"Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a Genetics of Diabetes Audit and Research Tayside study (GoDARTS).","date":"2017","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/28727628","citation_count":6,"is_preprint":false},{"pmid":"29479488","id":"PMC_29479488","title":"Does the Polymorphism in the Length of the Polyalanine Tract of FOXE1 Gene Influence the Risk of Thyroid Dysgenesis Occurrence?","date":"2017","source":"Journal of thyroid research","url":"https://pubmed.ncbi.nlm.nih.gov/29479488","citation_count":6,"is_preprint":false},{"pmid":"28928994","id":"PMC_28928994","title":"FOXE1 Mutation Screening in a Case with Cleft Lip, Hypothyroidism, and Thyroid Carcinoma: A New Syndrome?","date":"2017","source":"Case reports in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28928994","citation_count":6,"is_preprint":false},{"pmid":"34643920","id":"PMC_34643920","title":"Genetic predisposition of SNPs in miRNA-149 (rs2292832) and FOXE1 (rs3758249) in thyroid Cancer.","date":"2021","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/34643920","citation_count":5,"is_preprint":false},{"pmid":"33798911","id":"PMC_33798911","title":"YY1-induced up-regulation of FOXE1 is negatively regulated by miR-129-5p and contributes to the progression of papillary thyroid microcarcinoma.","date":"2021","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33798911","citation_count":5,"is_preprint":false},{"pmid":"20094846","id":"PMC_20094846","title":"Characterization of mutations in the FOXE1 gene in a cohort of unrelated Malaysian patients with congenital hypothyroidism and thyroid dysgenesis.","date":"2009","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20094846","citation_count":5,"is_preprint":false},{"pmid":"27474100","id":"PMC_27474100","title":"Association of FOXE1 polyalanine repeat region with thyroid cancer is dependent on tumour size.","date":"2016","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/27474100","citation_count":5,"is_preprint":false},{"pmid":"26206751","id":"PMC_26206751","title":"TITF1 and TITF2 loci variants indicate significant associations with thyroid cancer.","date":"2015","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/26206751","citation_count":4,"is_preprint":false},{"pmid":"36994096","id":"PMC_36994096","title":"Disruption of the foxe1 gene in zebrafish reveals conserved functions in development of the craniofacial skeleton and the thyroid.","date":"2023","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/36994096","citation_count":4,"is_preprint":false},{"pmid":"21999483","id":"PMC_21999483","title":"Accelerated evolution of 3'avian FOXE1 genes, and thyroid and feather specific expression of chicken FoxE1.","date":"2011","source":"BMC evolutionary biology","url":"https://pubmed.ncbi.nlm.nih.gov/21999483","citation_count":4,"is_preprint":false},{"pmid":"34070861","id":"PMC_34070861","title":"Further Evidence That Defects in Main Thyroid Dysgenesis-Related Genes Are an Uncommon Etiology for Primary Congenital Hypothyroidism in Mexican Patients: Report of Rare Variants in FOXE1, NKX2-5 and TSHR.","date":"2021","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34070861","citation_count":4,"is_preprint":false},{"pmid":"38296906","id":"PMC_38296906","title":"FOXE1 Gene is a Probable Tumor Suppressor Gene with Decreased Expression as Papillary Thyroid Cancers Grow, and is Absent in Anaplastic Thyroid Cancers.","date":"2024","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38296906","citation_count":2,"is_preprint":false},{"pmid":"34299284","id":"PMC_34299284","title":"FOXE1-Dependent Regulation of Macrophage Chemotaxis by Thyroid Cells In Vitro and In Vivo.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34299284","citation_count":2,"is_preprint":false},{"pmid":"37733420","id":"PMC_37733420","title":"Immunohistochemical Evaluation of BARX1, DLX4, FOXE1, HOXB3, and MSX2 in Nonsyndromic Cleft Affected Tissue.","date":"2022","source":"Acta medica Lituanica","url":"https://pubmed.ncbi.nlm.nih.gov/37733420","citation_count":2,"is_preprint":false},{"pmid":"35963604","id":"PMC_35963604","title":"A new FOXE1 homozygous frameshift variant expands the genotypic and phenotypic spectrum of Bamforth-Lazarus syndrome.","date":"2022","source":"European journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35963604","citation_count":2,"is_preprint":false},{"pmid":"29509083","id":"PMC_29509083","title":"Association of SNP rs1867277 in FOXE1 Gene and Cleft Lip with or without Cleft Palate in a Han Chinese Population.","date":"2018","source":"Fetal and pediatric pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29509083","citation_count":2,"is_preprint":false},{"pmid":"37435181","id":"PMC_37435181","title":"FOXE1 polymorphism rs965513 predisposes to thyroid cancer in a European cohort.","date":"2021","source":"Endocrine oncology (Bristol, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37435181","citation_count":2,"is_preprint":false},{"pmid":"32986379","id":"PMC_32986379","title":"Network-Based Analysis Reveals Association of FOXE1 Gene Polymorphisms in Thyroid Cancer Patients; A Case-Control Study in Southeast of Iran.","date":"2020","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/32986379","citation_count":2,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53307,"output_tokens":9008,"usd":0.14752,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19132,"output_tokens":7772,"usd":0.14498,"stage2_stop_reason":"end_turn"},"total_usd":0.2925,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"TTF-2 (FOXE1) is a forkhead domain-containing transcription factor that binds to sites on both thyroglobulin (Tg) and thyroperoxidase (TPO) promoters. Its expression is transient in the developing thyroid and is down-regulated just before the onset of Tg and TPO gene expression, suggesting it acts as a negative controller of thyroid-specific gene expression during development.\",\n      \"method\": \"cDNA cloning, DNA binding assays, expression analysis by in situ hybridization in mouse embryos\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — original cloning paper with direct DNA binding assays and in vivo expression mapping; foundational study replicated by subsequent work\",\n      \"pmids\": [\"9214635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"TTF-2 (FOXE1) mRNA levels are under transcriptional control by TSH (via cAMP), insulin, and IGF-I in FRTL-5 thyroid cells. TSH and insulin effects are additive, require ongoing protein synthesis, and increase TTF-2 transcription rates as demonstrated by run-off assays.\",\n      \"method\": \"Northern blot, nuclear run-off transcription assays, dose-response experiments in FRTL-5 thyroid cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct transcription rate measurement by run-off assay combined with dose-response and protein synthesis inhibition in a well-established thyroid cell model\",\n      \"pmids\": [\"9287345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"A homozygous missense mutation (Ala65Val) within the FOXE1 forkhead domain causes thyroid agenesis, cleft palate, and choanal atresia. The mutant protein exhibits impaired DNA binding and loss of transcriptional function.\",\n      \"method\": \"Patient sequencing, in vitro DNA binding assays, transcriptional reporter assays with mutant protein\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — functional validation by direct DNA binding and transcription assays combined with human genetics; replicated in subsequent mutation reports\",\n      \"pmids\": [\"9697705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TTF-2 (FOXE1) physically interacts with CTF/NF-1 proteins (specifically CTF/NF1-C, which is itself TSH-, cAMP-, and insulin-inducible) via GST pull-down. This interaction enhances hormone-induced TPO gene expression; spacing between the two transcription factor binding sites is critical for promoter activity and hormonal response.\",\n      \"method\": \"GST pull-down assays, transfection experiments, protein-DNA interaction studies, spacing mutagenesis of TPO promoter\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — direct physical interaction demonstrated by GST pulldown; functional consequence confirmed by promoter mutagenesis and transfection in a single rigorous study\",\n      \"pmids\": [\"10329730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TTF-2 (FOXE1) acts as a promoter-specific transcriptional repressor of TTF-1 and Pax-8 activity through a DNA-binding-independent mechanism. The minimal repressor domain was identified as an independent functional domain that interferes with a specific cofactor required for TTF-1 and Pax-8 activity.\",\n      \"method\": \"Transcriptional reporter assays, deletion mutagenesis to map repressor domain, co-transfection experiments\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional repressor domain mapped by mutagenesis with reporter assays, but single lab and limited orthogonal validation\",\n      \"pmids\": [\"10944465\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A second homozygous missense mutation in TTF-2/FOXE1 (Ser57Asn in the forkhead DNA binding domain) causes congenital hypothyroidism, athyreosis, and cleft palate. The S57N mutant protein shows impaired DNA binding and partial loss of transcriptional function, correlating with a less severe phenotype than the A65V mutation.\",\n      \"method\": \"Patient sequencing, in vitro DNA binding assays, transcriptional reporter assays\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — functional DNA binding and transcription assays; genotype-phenotype correlation across two distinct mutations establishes structure-function relationship\",\n      \"pmids\": [\"12165566\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"TTF-2/FOXE1 protein is phosphorylated in vivo and is expressed in multiple endoderm-derived structures during mouse embryogenesis (tongue, palate, epiglottis, pharynx, oesophagus, choanae) and ectodermal structures (whiskers), consistent with the full phenotypic spectrum of Bamforth syndrome.\",\n      \"method\": \"Detailed immunohistochemistry of mouse embryos at multiple developmental stages, phosphorylation detection\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — phosphorylation of TTF-2 shown by fractionation/immunodetection; expression pattern established by systematic IHC across embryogenesis in a focused study\",\n      \"pmids\": [\"12203737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FOXE1 is a direct transcriptional target of GLI2 in the Sonic Hedgehog signaling pathway in human epidermis. A 2.5 kb upstream fragment containing five GLI-binding sites activates FOXE1 transcription in a reporter assay, with induction kinetics similar to the known direct GLI2 target PTCH.\",\n      \"method\": \"Reporter assays with GLI-binding site-containing FOXE1 upstream fragment, in situ hybridization, kinetic expression analysis\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay with defined binding sites plus expression co-localization; single lab, two complementary methods\",\n      \"pmids\": [\"15140221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Foxe1 is required for hair follicle morphogenesis downstream of the Shh/Gli pathway. In Foxe1-null mice, hair follicles are disoriented and misaligned. Dominant-negative Gli2 suppresses Foxe1 expression in hair follicles, and transcriptionally active Gli2 stimulates the Foxe1 promoter.\",\n      \"method\": \"Foxe1-null mouse analysis, dominant-negative Gli2 transgenic mice, Foxe1 promoter reporter assays, immunohistochemistry, lineage marker expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — loss-of-function mouse model with defined phenotype, epistasis established by dominant-negative approach, and promoter assay; multiple orthogonal methods in one study\",\n      \"pmids\": [\"15367491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"A third homozygous missense mutation in FOXE1 (R102C, within the forkhead DNA binding domain) causes loss of DNA binding and transcriptional inactivity but does not prevent thyroid tissue formation, indicating that human thyroid development can occur despite loss of TTF-2/FOXE1 function.\",\n      \"method\": \"Patient sequencing, in vitro DNA binding assay, transcriptional reporter assays\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — same functional assay platform replicated across three independent mutations; mechanistically informative negative phenotype (thyroid present despite null function)\",\n      \"pmids\": [\"16882747\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FoxE1 acts as a pioneer transcription factor: it binds to the compacted chromatin of the inactive TPO promoter upon hormone induction, creates a local exposed chromatin domain on H1-compacted nucleosome arrays even when its binding site is nucleosome-protected, and enables NF-1 to bind simultaneously with an additive effect on chromatin remodeling.\",\n      \"method\": \"Chromatin DNase I hypersensitivity assay in thyroid cells, in vitro nucleosome binding assays, in vitro H1-compacted chromatin assays, cotransfection/binding with NF-1\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with nucleosomes plus cell-based chromatin assays with multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"17709379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The FOXE1 polyalanine tract length modulates transcriptional activity: constructs with 16 alanines show 1.55-fold higher transcriptional activity than those with 14 alanines, while nuclear localization is not affected. The 16/16 genotype is associated with protection against thyroid dysgenesis.\",\n      \"method\": \"Transcriptional reporter assays with FOXE1 constructs containing 14 or 16 alanines, nuclear localization assessment, case-control and TDT association study\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assay directly comparing alanine tract variants; single lab, supported by genetic association data\",\n      \"pmids\": [\"17717707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The FOXE1 5' UTR variant rs1867277 (NM_004473.3:c.-283G>A) differentially recruits transcription factors: the A allele exclusively recruits USF1/USF2, while both alleles form a complex with DREAM/CREB/αCREM. Transfection studies show allele-dependent transcriptional regulation of FOXE1.\",\n      \"method\": \"DNA-binding (EMSA) assays, transfection reporter assays, candidate gene association study in Spanish and Italian cohorts\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct protein-DNA binding assays (EMSA) combined with functional transcription assays and replicated genetic association; multiple orthogonal methods\",\n      \"pmids\": [\"19730683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In non-syndromic cleft palate patients, a C→G polymorphism in the 5'-UTR of FOXE1 falls within a MYF-5 consensus binding motif and abolishes MYF-5 binding (demonstrated by EMSA), resulting in significantly reduced FOXE1 mRNA expression.\",\n      \"method\": \"DNA sequencing, EMSA/band-shift assays, oligonucleotide competition, real-time PCR\",\n      \"journal\": \"Journal of oral pathology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA directly demonstrates abolished MYF-5 binding with functional mRNA consequence; single lab\",\n      \"pmids\": [\"19192046\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In zebrafish, foxe1 loss-of-function (morpholino knockdown) causes abnormal craniofacial development with shortening of Meckel's cartilage and ceratohyals, suppressed chondrocytic proliferation, and reduced expression of sox9a, colIIa1, and runx2b at 2 dpf, while upregulating fgfr2 in branchial arches. Neural crest migration and pharyngeal arch specification are unaffected.\",\n      \"method\": \"Morpholino antisense knockdown in zebrafish, in situ hybridization for marker genes, cartilage staining\",\n      \"journal\": \"Journal of experimental zoology. Part B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific molecular marker readouts; zebrafish morpholino approach, single lab\",\n      \"pmids\": [\"19488987\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FOXE1 directly transactivates MSX1 and TGF-β3 promoters by binding to specific motifs, as demonstrated by ChIP and promoter reporter assays. Forkhead-domain mutations (but not polyalanine stretch polymorphisms) abolish this activity. In Foxe1-null mouse embryos (E14), Tgf-β3 and Msx1 mRNAs are nearly absent in palatal shelves, establishing these as direct FOXE1 targets required for palatogenesis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), promoter reporter (transactivation) assays, Foxe1-null mouse embryo analysis by RT-PCR, mutagenesis of forkhead domain\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — ChIP plus reporter assays plus in vivo knockout validation; multiple orthogonal methods with mutagenesis\",\n      \"pmids\": [\"21177256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"A fourth homozygous FOXE1 missense mutation (F137S, caused by maternal isodisomy of chromosome 9) abolishes DNA binding and transcriptional activity as predicted by structural modeling and confirmed by transfection assays.\",\n      \"method\": \"Sequencing, microsatellite marker analysis, MLPA, structural modeling, transfection transcriptional assays\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional validation by transcription assay plus structural modeling; confirms established pattern across four independent mutations\",\n      \"pmids\": [\"20484477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"FOXE1 polyalanine tract length affects transcriptional function: in vitro studies show FOXE1(16Ala) is transcriptionally impaired compared to FOXE1(14Ala), without differences in protein expression or DNA binding, suggesting the alanine tract modulates a step after DNA binding (e.g., cofactor interaction or transactivation).\",\n      \"method\": \"In vitro transcriptional reporter assays, protein expression analysis, DNA binding assays comparing different polyalanine tract length variants\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three functional parameters measured to localize the functional defect; single lab\",\n      \"pmids\": [\"22736773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FoxE1 directly binds the NIS (Nis) upstream enhancer and the Duox2 regulatory region in thyroid cells (demonstrated by ChIP), with simultaneous binding of FoxE1 and NF1/CTF to the Nis enhancer having an additive functional effect on Nis promoter activation. Genome-wide expression screening after FoxE1 knockdown identified multiple regulated targets including Adamts9, Cdh1, Duox2, S100a4 (upregulated) and Casp4, Creld2, Dusp5, Etv5, Hsp5a, Nr4a2, Tm4sf1 (downregulated).\",\n      \"method\": \"Genome-wide expression screening after FoxE1 knockdown, ChIP assay, in silico promoter analysis, luciferase reporter assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — ChIP demonstrates direct genomic binding, combined with genome-wide knockdown expression profiling and reporter assays; multiple orthogonal methods in one study\",\n      \"pmids\": [\"23675434\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Methylation of two consecutive CpG dinucleotides (CpG14 and CpG15) in the FOXE1 promoter (-1600 to -1140 from TSS) is significantly higher in leukocytes than in thyroid tissue, and this methylation reduces FOXE1 promoter activity in luciferase assays. Preventing methylation of these sites by mutation restores promoter activity.\",\n      \"method\": \"Genome-wide methylation array, bisulfite sequencing, luciferase reporter assays with methylated and unmethylated FOXE1 promoter constructs, site-directed mutagenesis of CpG sites\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro methylation + reporter assay with mutagenesis directly demonstrates functional consequence of specific CpG methylation; multiple orthogonal methods\",\n      \"pmids\": [\"24646064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A non-coding SNP (rs7850258) within a -67.7 kb FOXE1 enhancer element active in oral epithelium and developing thyroid alters enhancer activity in an allele-dependent manner: the G allele (associated with CLP and hypothyroidism) has significantly greater enhancer activity than the A allele (associated with thyroid cancer). The element is more responsive to MYC and ARNT with the G allele, as predicted by transcription factor binding differences.\",\n      \"method\": \"Zebrafish and mouse transgenesis to identify enhancers, quantitative reporter assays in oral epithelial and thyroid cell lines comparing both alleles, transcription factor binding prediction\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo enhancer identification by transgenesis in two model organisms plus quantitative reporter assays; directly links non-coding variant to FOXE1 expression differences\",\n      \"pmids\": [\"25652407\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXE1 somatic mutations in papillary thyroid cancer (P54Q, K95Q, L112F in PTC; G140R in MNG) within the forkhead domain result in marked impairment of transcriptional activation without affecting protein expression, as demonstrated by in vitro functional assays and molecular modeling.\",\n      \"method\": \"Sequencing of 120 PTC and 110 MNG samples, in vitro transcriptional activation assays, FOXE1 forkhead domain structural modeling\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays for all four mutants; molecular modeling provides structural rationale; single lab\",\n      \"pmids\": [\"25950909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXE1 germline variant p.A248G promotes cell proliferation and migration in rat normal thyroid cells (PCCL3) and human PTC cell line (TPC-1), suggesting a gain-of-function or altered function in thyroid tumorigenesis.\",\n      \"method\": \"Stable expression of wild-type and p.A248G mutant FOXE1 in thyroid cell lines, proliferation and migration assays\",\n      \"journal\": \"Endocrine\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — cell-based proliferation and migration assays without mechanistic pathway identification; single lab, single functional readout\",\n      \"pmids\": [\"25381600\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FOXE1 expression is regulated by TSH/cAMP via CREB and CREM binding to CRE sites in the Foxe1 promoter, and by TGF-β via SMAD proteins that inhibit TSH-induced Foxe1 expression. Foxe1 is also regulated by Nkx2-1, Pax8, and by itself (autoregulation), establishing a complex transcriptional network for Foxe1 control in thyroid follicular cells.\",\n      \"method\": \"Promoter cloning, site-directed mutagenesis of CRE and SMAD binding sites, protein/DNA binding assays, siRNA gene silencing of CREB/CREM/Smad/Nkx2-1/Pax8, reporter assays in PCCl3 thyroid cells\",\n      \"journal\": \"Thyroid\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — systematic promoter mutagenesis combined with binding assays and siRNA knockdown of each regulatory factor; multiple orthogonal methods in one study\",\n      \"pmids\": [\"30652527\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Nitric oxide (NO) inhibits TSH-stimulated TPO expression by repressing FoxE1 expression through a cGMP-dependent protein kinase-mediated pathway. The FoxE1 binding site Z in the TPO promoter mediates the NO-inhibited TPO expression.\",\n      \"method\": \"NO donor treatment of FRTL-5 thyroid cells, cGMP-PKG pathway inhibitor studies, promoter binding site mutation analysis, FoxE1 expression measurement\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with specific binding site identified as mediator; single lab but mechanistically defined pathway\",\n      \"pmids\": [\"26610751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FOXE1 physically interacts with ELK1 (identified in a transcription factor binding array, confirmed by co-immunoprecipitation and mammalian two-hybrid assay). In thyroid tissue, endogenous FOXE1 and ELK1 bind the TERT and TPO promoters in close proximity (ChIP assay). FOXE1 positively regulates TERT expression in a manner dependent on its association with ELK1; MEK inhibition (U0126) disrupts the FOXE1-ELK1 interaction and reduces TERT and TPO promoter activity.\",\n      \"method\": \"Transcription factor binding array, co-immunoprecipitation, mammalian two-hybrid assay, ChIP in human thyroid tissue, EMSA, TERT promoter reporter assays, siRNA silencing, MEK inhibitor treatment\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — physical interaction confirmed by reciprocal co-IP and two-hybrid; ChIP in native tissue; functional consequence shown by reporter assay and siRNA; multiple orthogonal methods\",\n      \"pmids\": [\"27852061\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Foxe1 overexpression in mouse thyroid (under thyroglobulin promoter) causes early severe hypothyroidism and thyroid hypoplasia, then multinodular goiter with macrofollicular-papilloid benign nodules in adult mice. Combined with radiation or Pten haploinsufficiency, Foxe1 overexpression promotes hyperplastic but not malignant nodule formation, indicating proper Foxe1 dosage is essential for normal thyroid structure and function.\",\n      \"method\": \"Transgenic mouse model (Tg-Foxe1), thyroid hormone measurement, histological analysis, radiation exposure experiments, crossing with Pten+/- mice\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo transgenic model with quantitative hormone measurement and histology; multiple genetic backgrounds tested; direct dose-effect demonstrated\",\n      \"pmids\": [\"26982637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PTCSC2 lncRNA binds MYH9 (myosin-9) protein. In a bidirectional promoter shared by FOXE1 and PTCSC2, MYH9 inhibits promoter activity in both directions; PTCSC2 reverses this inhibition. RNA knockdown of FOXE1 in primary thyroid cells profoundly interferes with the p53 pathway.\",\n      \"method\": \"RNA pull-down/binding assay (PTCSC2-MYH9 interaction), bidirectional promoter reporter assays, siRNA knockdown of FOXE1 with pathway gene expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-protein binding and promoter reporter assays demonstrated; FOXE1 knockdown pathway effect shown; single lab\",\n      \"pmids\": [\"28049826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FOXE1 directly binds the HK2 promoter and negatively regulates HK2 transcription, thereby suppressing the Warburg effect (aerobic glycolysis) in colorectal cancer cells. Silencing FOXE1 enhances glucose consumption and lactate production, while enforced FOXE1 expression has opposite effects.\",\n      \"method\": \"ChIP assay showing FOXE1 binding to HK2 promoter, luciferase reporter assays, FOXE1 knockdown/overexpression with metabolic measurements, in vivo xenograft\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrates direct promoter binding; functional metabolic phenotype confirmed in vitro and in vivo; single lab\",\n      \"pmids\": [\"31918722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"FOXE1 directly interacts with the ZEB1 promoter (confirmed by ChIP) and positively regulates ZEB1 transcriptional activity. Loss of FOXE1 decreases ZEB1 expression, while FOXE1 overexpression increases ZEB1 activity. ZEB1 silencing reduces thyroid tumor cell migration and invasion, placing FOXE1 upstream of ZEB1 in an EMT regulatory pathway.\",\n      \"method\": \"ChIP assay, gain-of-function and loss-of-function experiments, ZEB1 reporter assays, migration/invasion assays, siRNA silencing of ZEB1 and FOXE1\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirms direct binding; epistasis established by sequential knockdown; functional readout in migration/invasion; single lab\",\n      \"pmids\": [\"31846430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Reducing FOXE1 gene dosage (FOXE1+/- background) in a BRAFV600E-inducible thyroid cancer mouse model changes cancer histology: FOXE1+/+ cancers resemble high-grade papillary thyroid carcinomas while FOXE1+/- cancers are morphologically less malignant but more severely undifferentiated, with reduced proliferation and increased apoptosis. FOXE1 dosage thus exerts pleiotropic effects on thyroid cancer histology and differentiation markers.\",\n      \"method\": \"Genetic epistasis in compound transgenic mouse model, histological analysis, proliferation index (Ki67), apoptosis assay, immunohistochemistry for differentiation markers\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean genetic dosage experiment in defined in vivo cancer model with multiple phenotypic readouts; single lab\",\n      \"pmids\": [\"33375029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FOXE1 expression in thyroid cells (that do not endogenously express FOXE1) upregulates multiple chemokines involved in macrophage recruitment. FOXE1-expressing cells induce chemotaxis of co-cultured monocytes. In a mouse thyroid cancer model, FOXE1 dosage directly correlates with expression of the same chemokine set, and pro-tumorigenic M2 macrophage infiltration is decreased in tumors with reduced FOXE1.\",\n      \"method\": \"Transcriptome analysis (RNA-seq) after FOXE1 expression in FOXE1-negative cells, monocyte chemotaxis co-culture assay, in vivo mouse cancer model with FOXE1+/- background, immunohistochemistry for macrophage markers\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transcriptomic plus functional chemotaxis assay plus in vivo validation; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"34299284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Tamoxifen-inducible ubiquitous deletion of Foxe1 in adult mice causes disrupted thyroid follicular architecture, elevated TSH, reduced T4, decreased Tpo and Tg expression, and an unexpected increase in thyroidal mast cells (marked by Mcpt4 and Ctsg), confirming Foxe1's role in maintenance of thyroid differentiation in adults.\",\n      \"method\": \"Conditional knockout mouse model (Cre-lox/tamoxifen inducible), hormone measurements, histology, immunohistochemistry, microarray and RNA-seq transcriptomics, RT-qPCR validation\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible conditional knockout with multiple functional readouts (hormone levels, histology, transcriptomics) confirms adult role; mechanistically links FOXE1 loss to mast cell infiltration\",\n      \"pmids\": [\"36156081\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"FOXE1 promotes keratinocyte proliferation by facilitating G1/S transition and activating ERK1/2 signaling, and upregulates the production of IL-1β, IL-6, and TNF-α. RNA-seq identifies WNT5A as a downstream effector; WNT5A knockdown inhibits FOXE1-driven keratinocyte proliferation and cytokine production. In vivo, FOXE1 depletion by shRNA or genetic deletion ameliorates imiquimod-induced psoriasis-like dermatitis.\",\n      \"method\": \"Knockdown and overexpression of FOXE1 in keratinocytes, RNA-seq, cell cycle analysis, ERK1/2 phosphorylation assay, WNT5A siRNA rescue experiment, imiquimod mouse model with lentiviral shRNA or genetic FOXE1 deletion\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq identifies WNT5A as downstream target; epistasis confirmed by rescue experiment; in vivo validation in mouse model; single lab\",\n      \"pmids\": [\"37394057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HR (Hairless) transcriptional cofactor suppresses Foxe1 mRNA expression in skin; Foxe1 downregulation in turn reduces Msx1 expression in hair follicles, placing HR upstream of Foxe1 and Msx1 in a hair follicle regulatory cascade. Sfrp1 expression also correlates with Foxe1 levels.\",\n      \"method\": \"Expression analysis in HR-overexpressing mouse skin and keratinocytes, correlation of Foxe1 and downstream target gene expression\",\n      \"journal\": \"BMB reports\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — correlation of expression in overexpression model without direct mechanistic binding or epistasis experiment; single lab, single method\",\n      \"pmids\": [\"21777520\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FOXE1 (TTF-2) is a forkhead domain transcription factor that functions as a pioneer factor in thyroid differentiation—binding compacted chromatin at the TPO promoter to enable access by other factors—and directly activates transcription of thyroid differentiation genes (TPO, Tg, NIS, Duox2) while repressing others (HK2); its transcription is induced by TSH/cAMP (via CREB/CREM), insulin/IGF-I, and thyroid transcription factors Nkx2-1 and Pax8 (with autoregulation), and is inhibited by TGF-β/SMAD and nitric oxide; FOXE1 physically interacts with CTF/NF-1 and ELK1 to co-regulate target promoters (including TERT), and co-regulates ZEB1, MSX1, TGF-β3, and chemokines involved in macrophage recruitment; loss-of-function mutations in its forkhead domain abolish DNA binding and cause congenital hypothyroidism with thyroid agenesis, cleft palate, and choanal atresia (Bamforth-Lazarus syndrome), while proper gene dosage is essential for normal thyroid architecture in adults, and non-coding variants near FOXE1 alter enhancer activity to modulate susceptibility to thyroid cancer, hypothyroidism, and orofacial clefting.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FOXE1 (TTF-2) is a forkhead-domain transcription factor that orchestrates thyroid follicular cell differentiation and is also required for craniofacial and skin development [#0, #2]. It functions as a pioneer factor, binding the compacted, nucleosome-protected chromatin of the inactive TPO promoter upon hormone induction to create a locally accessible chromatin domain that enables co-occupancy by NF-1/CTF, with additive effects on chromatin remodeling and target activation [#10, #3]. Through its forkhead domain it directly binds and transactivates a battery of thyroid differentiation genes including TPO, Tg, the NIS enhancer, and Duox2 [#0, #18], and during palatogenesis it directly drives MSX1 and TGF-\\u03b23 [#15]; conversely it represses targets such as HK2 to restrain aerobic glycolysis [#28]. FOXE1 also partners with ELK1 to co-occupy and activate the TERT and TPO promoters in a MEK-dependent manner [#25], and acts upstream of ZEB1 in an EMT/migration program [#29]. FOXE1 transcription is itself a signaling integration node: it is induced by TSH/cAMP through CREB/CREM and by insulin/IGF-I, autoregulated and co-controlled by Nkx2-1 and Pax8, and inhibited by TGF-\\u03b2/SMAD and by nitric oxide via cGMP-dependent kinase [#1, #23, #24], with additional control by GLI2/Sonic Hedgehog in epidermis [#7, #8]. Homozygous missense mutations in the forkhead domain abolish DNA binding and transcriptional activity and cause Bamforth-Lazarus syndrome\\u2014congenital hypothyroidism with thyroid agenesis, cleft palate, and choanal atresia [#2, #5, #9, #16]. Proper FOXE1 gene dosage is essential for normal thyroid architecture, hormone production, and tumor differentiation in adults, and non-coding variants near FOXE1 alter enhancer or promoter activity to modulate susceptibility to thyroid dysgenesis, thyroid cancer, hypothyroidism, and orofacial clefting [#26, #32, #20, #12].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established the molecular identity of FOXE1 as a forkhead transcription factor that physically binds thyroid-specific promoters, defining its core activity in thyroid gene regulation.\",\n      \"evidence\": \"cDNA cloning, DNA-binding assays, and in situ hybridization in mouse embryos\",\n      \"pmids\": [\"9214635\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs. repressive role on target genes ambiguous from expression timing alone\", \"No structural definition of DNA-binding specificity\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Defined the upstream signaling inputs by showing FOXE1 transcription is hormonally controlled, linking it to thyroid-stimulating and growth-factor signaling.\",\n      \"evidence\": \"Northern blot and nuclear run-off transcription assays in FRTL-5 thyroid cells\",\n      \"pmids\": [\"9287345\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter elements mediating TSH/insulin response not yet mapped\", \"Transcription factors transducing the signal unidentified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Connected FOXE1 to human disease by demonstrating that a forkhead-domain mutation abolishing DNA binding causes thyroid agenesis with cleft palate, establishing FOXE1 as causative for Bamforth-Lazarus syndrome.\",\n      \"evidence\": \"Patient sequencing with in vitro DNA-binding and transcriptional reporter assays of the A65V mutant\",\n      \"pmids\": [\"9697705\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single mutation; allelic series not yet established\", \"Mechanism linking loss of binding to specific tissue agenesis unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identified the first FOXE1 protein partner, showing it cooperates with hormone-inducible CTF/NF-1 to potentiate TPO promoter activity in a spacing-dependent manner.\",\n      \"evidence\": \"GST pull-down, TPO promoter spacing mutagenesis, and transfection assays\",\n      \"pmids\": [\"10329730\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether cooperation requires chromatin context not addressed\", \"Endogenous co-occupancy not yet shown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Revealed a DNA-binding-independent repressor function, showing FOXE1 can interfere with TTF-1/Pax-8 cofactors and thereby has dual activator/repressor capacity.\",\n      \"evidence\": \"Deletion mutagenesis mapping a repressor domain with co-transfection reporter assays\",\n      \"pmids\": [\"10944465\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The targeted cofactor not identified\", \"Single lab, limited orthogonal validation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Built a genotype-phenotype structure-function relationship by correlating a partial-function forkhead mutation (S57N) with a milder phenotype than A65V.\",\n      \"evidence\": \"Patient sequencing with DNA-binding and reporter assays\",\n      \"pmids\": [\"12165566\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual function quantification approximate\", \"Modifiers of phenotype severity unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapped FOXE1 expression beyond thyroid to multiple endoderm- and ectoderm-derived structures and showed it is phosphorylated, explaining the syndromic phenotypic spectrum.\",\n      \"evidence\": \"Systematic immunohistochemistry across mouse embryogenesis plus phosphorylation detection\",\n      \"pmids\": [\"12203737\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphorylation sites and kinases not identified\", \"Functional consequence of phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed FOXE1 downstream of Sonic Hedgehog by identifying it as a direct GLI2 target and a requirement for hair follicle morphogenesis, defining a non-thyroid developmental role.\",\n      \"evidence\": \"GLI-site reporter assays, Foxe1-null mice, and dominant-negative/active Gli2 epistasis\",\n      \"pmids\": [\"15140221\", \"15367491\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"FOXE1 effector genes in follicle morphogenesis not defined here\", \"Direct GLI2 occupancy at the FOXE1 locus not shown by ChIP\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Refined the developmental requirement by showing a complete loss-of-function mutation (R102C) still permits thyroid tissue formation in humans, indicating FOXE1 is dispensable for organ initiation but required for proper differentiation.\",\n      \"evidence\": \"Patient sequencing with DNA-binding and reporter assays\",\n      \"pmids\": [\"16882747\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why this null allele spares thyroid tissue unexplained\", \"Possible compensatory factors unidentified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the central mechanistic insight that FOXE1 is a pioneer factor, binding compacted chromatin to open it and license NF-1 co-binding, explaining how it initiates thyroid gene activation.\",\n      \"evidence\": \"DNase I hypersensitivity in thyroid cells and in vitro H1-compacted nucleosome reconstitution with NF-1\",\n      \"pmids\": [\"17709379\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Chromatin remodelers recruited not identified\", \"Genome-wide pioneer activity not assessed\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showed the FOXE1 polyalanine tract length tunes transcriptional output independent of localization, linking a coding polymorphism to thyroid dysgenesis risk.\",\n      \"evidence\": \"Reporter assays comparing 14- vs 16-alanine constructs with case-control/TDT association\",\n      \"pmids\": [\"17717707\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of alanine-tract effect not pinpointed (resolved later)\", \"Direction of effect later refined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated that non-coding regulatory variants modulate FOXE1 dosage by altering transcription factor recruitment, mechanistically connecting GWAS associations to FOXE1 expression in thyroid and cleft phenotypes.\",\n      \"evidence\": \"EMSA and reporter assays for the rs1867277 5'UTR variant (USF1/USF2, DREAM/CREB/CREM) and a cleft-associated UTR variant abolishing MYF-5 binding\",\n      \"pmids\": [\"19730683\", \"19192046\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo allelic expression effect in human tissue not directly measured\", \"Cell-type specificity of factor recruitment incomplete\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Extended the craniofacial role across species by showing foxe1 loss impairs cartilage development and chondrocyte gene expression in zebrafish.\",\n      \"evidence\": \"Morpholino knockdown with marker in situ hybridization and cartilage staining\",\n      \"pmids\": [\"19488987\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Morpholino specificity not genetically confirmed\", \"Direct vs indirect regulation of sox9a/runx2b unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified the direct palatogenesis target genes by showing FOXE1 binds and activates MSX1 and TGF-\\u03b23, which are lost in Foxe1-null palatal shelves, mechanistically explaining the cleft phenotype.\",\n      \"evidence\": \"ChIP, promoter reporter assays, forkhead-domain mutagenesis, and Foxe1-null embryo RT-PCR\",\n      \"pmids\": [\"21177256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether pioneer activity operates at these promoters not tested\", \"Cofactor requirements at MSX1/TGF-\\u03b23 unknown\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Added a fourth disease allele (F137S via uniparental isodisomy) reinforcing that forkhead-domain integrity is essential for DNA binding and transactivation.\",\n      \"evidence\": \"Sequencing, structural modeling, and transcription assays\",\n      \"pmids\": [\"20484477\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural model not experimentally validated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Localized the polyalanine-tract functional defect to a step downstream of DNA binding, refining how this coding variant modulates transactivation.\",\n      \"evidence\": \"Reporter assays comparing 14- vs 16-alanine variants with parallel protein-expression and DNA-binding measurements\",\n      \"pmids\": [\"22736773\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific cofactor or transactivation step affected unidentified\", \"Apparent direction differs from earlier study without reconciliation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Broadened the direct thyroid target repertoire genome-wide, showing FOXE1 binds the NIS enhancer and Duox2 region (with NF-1 additivity) and regulates many genes, consolidating its master role in follicular differentiation.\",\n      \"evidence\": \"Genome-wide expression profiling after FoxE1 knockdown plus ChIP and luciferase reporter assays\",\n      \"pmids\": [\"23675434\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect status of most knockdown-responsive genes unresolved\", \"Genome-wide binding map not generated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed promoter CpG methylation silences FOXE1, adding an epigenetic layer that may explain tissue-restricted expression.\",\n      \"evidence\": \"Bisulfite sequencing and reporter assays with methylated/mutated CpG14/15 constructs\",\n      \"pmids\": [\"24646064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes establishing methylation not identified\", \"In vivo methylation dynamics during development not traced\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Resolved how a single non-coding enhancer SNP can drive opposite disease associations by showing allele-dependent enhancer activity and differential MYC/ARNT responsiveness in oral and thyroid tissue.\",\n      \"evidence\": \"Zebrafish/mouse transgenesis enhancer mapping with allele-specific reporter assays\",\n      \"pmids\": [\"25652407\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous chromatin contacts to the FOXE1 promoter not mapped\", \"Quantitative effect on native FOXE1 levels not measured\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked FOXE1 to cancer by showing somatic forkhead-domain mutations in papillary thyroid carcinoma impair transactivation, implicating loss of FOXE1 differentiation function in tumorigenesis.\",\n      \"evidence\": \"Tumor sequencing with transcription assays and structural modeling\",\n      \"pmids\": [\"25950909\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream targets affected by these mutations not defined\", \"Driver vs passenger status not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined the TSH/cAMP and TGF-\\u03b2/NO regulatory circuitry controlling FOXE1, establishing it as an integration point for opposing thyroid signals.\",\n      \"evidence\": \"Promoter CRE/SMAD mutagenesis, binding assays, siRNA of CREB/CREM/SMAD/Nkx2-1/Pax8 in PCCl3 cells, and NO/cGMP-PKG pharmacology in FRTL-5 cells\",\n      \"pmids\": [\"30652527\", \"26610751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative hierarchy among inputs not established\", \"Crosstalk with chromatin/methylation control not integrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified ELK1 as a MEK-dependent FOXE1 partner co-regulating TERT and TPO, linking FOXE1 to telomerase control and MAPK signaling in thyroid cells.\",\n      \"evidence\": \"TF binding array, reciprocal co-IP, mammalian two-hybrid, ChIP in human thyroid tissue, reporter assays, siRNA, and MEK inhibition\",\n      \"pmids\": [\"27852061\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the interaction is direct or bridged not fully resolved\", \"Phosphorylation sites mediating MEK dependence unmapped\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that FOXE1 dosage is critical for thyroid architecture, with overexpression causing hypothyroidism, hypoplasia, and benign nodular disease.\",\n      \"evidence\": \"Tg-Foxe1 transgenic mice with hormone measurement, histology, radiation, and Pten+/- crosses\",\n      \"pmids\": [\"26982637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mediators of dosage sensitivity not defined\", \"Overexpression did not produce malignancy, leaving cancer role open\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Connected FOXE1 to its bidirectional partner lncRNA PTCSC2 and the p53 pathway, adding a regulatory and tumor-suppressive dimension to the locus.\",\n      \"evidence\": \"PTCSC2-MYH9 RNA pull-down, bidirectional promoter reporter assays, and FOXE1 knockdown pathway profiling\",\n      \"pmids\": [\"28049826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking FOXE1 to p53 genes not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed a metabolic regulatory role by showing FOXE1 directly represses HK2 to suppress the Warburg effect in colorectal cancer.\",\n      \"evidence\": \"ChIP, reporter assays, FOXE1 gain/loss with metabolic readouts and xenografts\",\n      \"pmids\": [\"31918722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether repression uses the DNA-binding-independent mechanism unknown\", \"Generalizability beyond colorectal context untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed FOXE1 upstream of ZEB1 in an EMT program, providing a mechanism for FOXE1 influence on thyroid tumor migration and invasion.\",\n      \"evidence\": \"ChIP, ZEB1 reporter assays, sequential siRNA epistasis, and migration/invasion assays\",\n      \"pmids\": [\"31846430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs cooperative activation of ZEB1 not fully distinguished\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed FOXE1 dosage exerts pleiotropic effects on cancer histology and differentiation in a BRAF-driven model, clarifying its role in tumor phenotype rather than initiation.\",\n      \"evidence\": \"Genetic dosage epistasis in BRAFV600E mice with proliferation, apoptosis, and marker analysis\",\n      \"pmids\": [\"33375029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Target genes mediating histological shift not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked FOXE1 to the tumor immune microenvironment by showing it drives chemokine expression and macrophage recruitment in a dosage-dependent manner.\",\n      \"evidence\": \"RNA-seq after FOXE1 expression, monocyte chemotaxis co-culture, and FOXE1+/- mouse cancer model with macrophage IHC\",\n      \"pmids\": [\"34299284\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chemokine promoter targets not all validated\", \"Whether effect is thyroid-specific unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a continued adult requirement by showing inducible Foxe1 deletion disrupts thyroid architecture, lowers hormone output, and unexpectedly increases mast cells.\",\n      \"evidence\": \"Tamoxifen-inducible conditional knockout with hormone, histology, and transcriptomic analyses\",\n      \"pmids\": [\"36156081\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of mast cell accumulation unknown\", \"Direct vs indirect basis of differentiation-gene loss not parsed\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined a pro-inflammatory skin role, showing FOXE1 drives keratinocyte proliferation and cytokine production via ERK1/2 and WNT5A and promotes psoriasis-like dermatitis.\",\n      \"evidence\": \"FOXE1 gain/loss in keratinocytes, RNA-seq, WNT5A rescue, and imiquimod mouse model with shRNA/genetic deletion\",\n      \"pmids\": [\"37394057\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether WNT5A is a direct FOXE1 target not shown\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FOXE1 pioneer activity is mechanistically coupled to specific chromatin remodelers, post-translational modifications, and its switch between activation and repression across tissues remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified remodeling complex recruited by FOXE1\", \"Phosphorylation sites and their regulatory roles unmapped\", \"Determinants selecting activator vs repressor mode unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 2, 15, 18, 23, 28]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 2, 5, 9, 10]},\n      {\"term_id\": \"GO:0140097\", \"supporting_discovery_ids\": [3, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 11]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 10, 15, 18, 23]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [10, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 14, 15]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 7, 23, 24, 25]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 5, 9, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"NF1\", \"CTF\", \"ELK1\", \"MYH9\", \"USF1\", \"USF2\", \"CREB\", \"MYF5\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}